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Abstract 
 
WHO recommends daily iron supplementation (60mg) for all pregnant women where 
anaemia prevalence exceeds 40%. However, recent evidence suggests that iron 
supplementation may be harmful as it increases the risks of hypertension and of infection. 
Iron absorption is regulated by hepcidin, a key iron regulatory hormone with the potential to 
be a useful marker to determine if oral iron can be absorbed effectively and safely. We 
aimed to identify a hepcidin threshold to define ’safe and ready’ to receive iron and then test 
whether a hepcidin-guided screen-and-treat approach to iron supplementation is non-inferior 
to the WHO-recommended universal daily supplementation.  
Method: We established our screening threshold by measuring haemoglobin and serum 
hepcidin, ferritin, iron, soluble transferrin receptor (sTfR), and C-reactive protein (CRP) at 14, 
20 and 30 week of gestation among 395 pregnant rural Gambian women using archived 
maternal blood samples (2010-2013), and analysed hepcidin’s diagnostic test accuracy 
[area under the receiver operating characteristic curve (AUCROC), sensitivity, specificity, cut 
offs] for iron deficiency at each time point. We established a threshold of 2.5µg/L. We then 
conducted a 3-arm randomised-controlled proof-of-concept trial in rural Gambia from June 
2014 to March 2016. We recruited 498 pregnant women aged 18-45 years with 14-22 weeks 
gestation to receive either: (A) UNU/UNICEF/WHO international multiple micronutrient 
preparation (UNIMMAP) containing iron 60mg/d; (B) UNIMMAP containing iron 60mg/d but 
based on a weekly hepcidin screening <2.5µg/L indicating if iron can be given for the next 7 
days or not; or (C): as in (B), but with iron 30mg/d. We report the per protocol analysis for 
primary and secondary outcomes at Day 84. We assessed non-inferiority with the primary 
endpoint being haemoglobin concentration at Day 84 with a non-inferiority margin of -5.0g/L. 
Results: The evidence for non-inferiority for screen-and-treat approaches using either 60mg 
iron (mean haemoglobin difference relative to Reference arm: -2.2g/L; 95% CI: -4.6, 0.1g/L) 
or 30mg iron (-2.7g/L; 95% CI: -5.0, -0.5g/L) was marginal. Anaemia (haemoglobin <110g/L) 
at the end of intervention was less prevalent in the Daily iron supplementation (Reference) 
arm than both Screen-and-treat arms. Among those without inflammation at the end of 
intervention, the prevalence of iron deficiency (ferritin <15ug/L) was less in the Reference 
arm compared to the two Screen-and-treat arms; corresponding prevalence values for 
transferrin saturation <16%; soluble transferrin receptor >4.4mg/L and hepcidin <2.5µg/L 
were lower in the Reference arm. The Screen-and-treat approaches had no added 
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advantage than universal daily iron supplementation in terms of adherence, side effects or 
safety outcomes. 
Conclusion: The daily 60mg iron supplementation arm performed better than both screen-
and-treat arms for anaemia and other iron markers (hepcidin, ferritin, soluble transferrin 
receptor, transferrin saturation). We therefore found no support for a screen-and-treat iron 
supplementation based on hepcidin concentration <2.5µg/L in pregnant Gambian women.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
 
Page 8 of 185 
 
Table of Contents 
 
Declaration ............................................................................................................................................ 2 
Dedication .............................................................................................................................................. 3 
Acknowledgement ................................................................................................................................ 4 
Abstract .................................................................................................................................................. 6 
Acronyms: ............................................................................................................................................ 10 
Chapter 1: Introduction ........................................................................................................................ 11 
1.1 Candidate’s involvement ................................................................................................... 11 
1.2 Scope and composition of the thesis .............................................................................. 11 
1.3 Supervisory team and collaborators: ............................................................................... 13 
1.4 Funding ................................................................................................................................ 13 
1.5 Study timeline ..................................................................................................................... 14 
Chapter 2: Background and literature review ................................................................................ 15 
2.1 Maternal anaemia and pregnancy outcome (maternal mortality): .............................. 15 
2.2 Maternal anaemia and iron status of the foetus and of infants ................................... 17 
2.3 Maternal anaemia and birth outcome: focus on low birth weight (LBW): .................. 22 
2.4 Current methods of assessing ID and IDA and their problems ................................... 25 
2.5 Potential for hepcidin to be an improved index of ‘safe and ready to receive’ iron: . 27 
2.6 Hepcidin and Pregnancy .................................................................................................... 30 
2.7 Need for a better point-of-care (PoC) diagnostic: ......................................................... 31 
2.8 Use of multiple micronutrient supplements .................................................................... 35 
Chapter 3: Protocol paper for HAPn................................................................................................ 38 
Chapter 4: Hepcidin cut-off paper .................................................................................................... 49 
Chapter 5: Hepcidin and anaemia in pregnancy (HAPn) Paper ................................................. 58 
Chapter 6: Summary discussion .................................................................................................... 132 
6.1 Current approaches to combatting ID and anaemia in pregnancy ........................... 132 
   
 
Page 9 of 185 
 
6.2 Evidence for efficacy of current approaches ................................................................ 132 
6.3 Limitations of current approaches .................................................................................. 133 
6.4 Alternative approaches for iron supplementation ........................................................ 133 
6.5 Could a screen-and-treat approach be better than a universal daily iron 
supplementation? ......................................................................................................................... 134 
6.6 Developing the diagnostic threshold ............................................................................. 134 
6.7 Testing the screen-and-treat approach ......................................................................... 134 
6.8 Potential explanation for why screen-and-treat did not work ..................................... 138 
6.9 Study limitations ............................................................................................................... 138 
6.10 Public health implications and policy recommendations ............................................ 139 
6.11 Future research needs .................................................................................................... 140 
6.12 How well was the overall aim of the study met? .......................................................... 141 
7 Appendices ............................................................................................................................ 143 
8 References ............................................................................................................................ 176 
 
Table 1: Timeline for the PhD .............................................................................................. 14 
Table 2: Limitation of current methods of assessing IDA ..................................................... 27 
 
Figure 1: Estimates of population-atributable risk of fetal anaemia in a highly malarious area 
in relation to maternal anaemia. .......................................................................................... 18 
Figure 2: Incidence of low birth weight (<2500 g) by haemoglobin concentration (g/L). ....... 23 
Figure 3: Adjusted odds ratios* (95% confidence intervals) for low birth weight (<2500 g) and 
preterm birth (<37 completed weeks) .................................................................................. 24 
Figure 4: Hepcidin regulates intestinal iron absorption, iron recycling by macrophages, and 
iron release from hepatic stores. ......................................................................................... 29 
Figure 5: Hepcidin regulation. ............................................................................................. 30 
Figure 6: Malaria susceptibility. ........................................................................................... 33 
Figure 7: Study location ...................................................................................................... 37 
   
 
Page 10 of 185 
 
 
Acronyms: 
AGP        Alpha-1 acid Glycoprotein 
AOR        Adjusted Odds Ratio 
CRP         C-reactive protein 
DSS        Demographic Surveillance 
System  
ID        Iron Deficiency 
IDA        Iron Deficiency Anaemia  
LBW        Low Birth Weight  
LSHTM London School of Hygiene and 
Tropical Medicine 
MRC- ING Medical Research Council    
International Nutrition Group 
MRC        Medical Research Council 
PI        Principal Investigator  
PVE        Plasma Volume Expansion  
RCT        Randomised Control Trial 
SCC                 Scientific Coordinating Committee 
SF        Serum Ferritin  
sTfR        soluble transferrin receptors  
TBI        Total Body Iron  
TIBC        Total Iron Binding Capacity 
TSAT        Transferrin Saturation  
WHO        World Health Organisation 
WIMM  Weatherall Institute of Molecular 
Medicine 
ZnPP        Zinc  Protoporphyrin 
   
 
Page 11 of 185 
 
Chapter 1: Introduction 
 
1.1 Candidate’s involvement 
 
After working for over two decades in many areas of nutrition policy and programme 
implementation including heading the micronutrient deficiency control programme in The 
Gambia, I developed a special interest in the control of anaemia among pregnant women 
and children. Therefore, when this opportunity to do a PhD arose, I undertook it.  The 
concept of this study was conceived by my supervisor, Prof Andrew M. Prentice and myself 
with input from Dr Sophie E. Moore.  I did all the background literature review; wrote the 
design; developed the study proposal and the trial protocols; and presented the proposal to 
both the MRC Scientific Coordinating Committee and the Gambia Government/MRC Ethics 
Committee for approval. The proposal was also submitted to the LSHTM Ethics Committee 
for approval. I was responsible for the identification of the study site and coordinated all the 
fieldwork which included the training and management of all field staff.  I assisted in the 
laboratory analysis of some of the samples and with the assistance of the data team in 
Keneba, I undertook all of the data cleaning and some basic statistical analysis.  I wrote this 
thesis and for the papers incorporated, I wrote the manuscripts and have the co-authors 
comments and contributions included.  All the authors approved the manuscripts before 
submission for publication. 
 
1.2 Scope and composition of the thesis 
 
The thesis is born out of the desire to contribute towards the appropriate management of 
anaemia and iron deficiency in pregnancy, as they are a global public health burden 
affecting both developed and developing countries.  Since the most significant contributor to 
the onset of anaemia worldwide is iron deficiency, WHO recommends universal iron 
supplementation for pregnant women.  However, recent studies and reviews show that not 
all pregnant women may need to receive universal iron supplementation.  This, coupled with 
the fact that studies have shown that higher haemoglobin levels may not necessarily lead to 
favourable pregnancy outcomes led to our idea of testing the hypothesis that a screen-and-
treat approach to iron supplementation using a predetermined hepcidin value of <2.5ug/L will 
be non-inferior to the reference universal daily iron supplementation level of 60mg iron 
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recommended by WHO, and would represent a safer approach to iron supplementation by 
reducing the amount of iron administered.  This PhD thesis is by a research paper style, 
where the research papers are incorporated in to the thesis as chapters: 
 
Chapter 1: The preface to the thesis summarises: my supervisory team and collaborators; 
the candidate’s involvement and declaration; the scope and composition of the thesis 
together with details of the source of funding and study timeline.  
  
Chapter 2: Summarises the background and literature review on maternal anaemia and 
pregnancy outcome; maternal anaemia and iron status of the foetus and of the infant; 
maternal anaemia and birth outcomes focusing on low birth weight; current methods of 
assessing iron deficiency and iron deficiency anaemia and their problems; the potential of 
hepcidin as an improved index for safe-and-ready to receive iron and the need for a better 
point-of-care (PoC) diagnostic for iron deficiency. 
 
Chapter 3: Is the published protocol paper. The paper describes the background to the main 
study of this thesis with its design and methods; study location; ethical permission and safety 
monitoring: informed consent and confidentiality as well as the sample size determination 
and the statistical analyses to be undertaken. Published in BMC Pregnancy and Childbirth 
(DOI:10.1186/s12884-016-0934-8).   
 
Chapter 4: Is a research paper co-authored by the student exploring the potential of 
hepcidin, entitled: Serum hepcidin declines in concentration during pregnancy and may 
identify iron deficiency: Analysis of a longitudinal pregnancy cohort in The Gambia.  The 
paper characterised the changes in hepcidin and indices of iron stores, erythropoiesis and 
inflammation in pregnancy and the assessment of hepcidin’s diagnostic potential as an index 
of iron deficiency. Published in the Journal of Nutrition 
(http://dx.doi.org/10.3945/jn.116.245373). 
 
Chapter 5: is the main research paper that examines the hypothesis that a screen-and-treat 
approach to iron supplementation is non-inferior to universal (daily) iron supplementation. 
The paper summarises the study outcome of the 498 pregnant women (gestational age 14 – 
22 weeks) recruited and randomised in to the 3 arms described in the protocol paper. Our 
data show a marginal non-inferiority for the screen-and-treat approaches (using 60mg or 
30mg iron) to the universal iron supplementation. The hepcidin-guided screen-and-treat 
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approaches were less efficacious in combatting iron deficiency and iron deficiency anaemia 
than universal daily iron supplementation and had no advantages in terms of adherence, 
side effects or safety outcomes. 
 
Chapter 6: Presents a summary discussion and conclusions including the study limitations, 
the public health implication and policy recommendation, and future research needs. 
 
1.3 Supervisory team and collaborators: 
 
Supervisor: 
Prof Andrew M. Prentice 
LSHTM, MRCG at LSHTM, UK. 
 
Associate Supervisor: 
Dr Sophie E. Moore 
King’s College London, UK 
 
Advisory Committee Members: 
Dr Hans Verhoef,  
Senior Lecturer, LSHTM, UK. 
 
Dr Kalifa Bojang  
MRCG at LSHTM, The Gambia. 
 
Dr Rita Wegmuller 
MRCG at LSHTM, The Gambia. 
 
Collaborators and collaborating institutions: 
Dr Hal Drakesmith, Dr Sant-Rayn Pasricha, Dr Andrew E. Armitage and team, WIMM, 
University of Oxford, United kingdom 
Dr Lorna Cox and team, MRC Elsie Widdowson Laboratory (MRC-EWL), Cambridge, UK 
Dr Carla Cerami, MRCG at LSHTM, The Gambia 
 
1.4 Funding  
 
The PhD is funded by the UK Medical Research Council (MRC) and the UK Department for 
International Development (DFID), under the MRC/DFID Concordat agreement to the MRC 
International Nutrition Group (MRC-ING), grant MC-A760-5QX00 and the research by the 
Bill & Melinda Gates Foundation (OPP 1055865) awarded to MRC-ING. 
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1.5 Study timeline 
The timeline for the PhD work is shown in Table 1. The PhD started as a full time 
programme but after the recruitment of the study participants for the first cohort, we realised 
that we could not complete the required sample size within the anticipated timeframe.  
Therefore, my supervisor and Faculty Research Degree Director recommended that I resort 
to part-time to enable me finish the field work and the PhD on time. 
Table 1: Timeline for the PhD 
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Chapter 2: Background and literature review 
 
Anaemia is a global public health problem affecting both developing and developed 
countries with major consequences for human health, social and economic development [1].  
Anaemia affects all population groups but those at greatest risk are pregnant women and 
children [2]. For women, consequences of anaemia include poor pregnancy and birth 
outcomes including premature delivery, low birth weight and increased perinatal mortality [3].  
 
2.1 Maternal anaemia and pregnancy outcome (maternal mortality): 
  
The impact of anaemia on maternal mortality has been demonstrated in many studies and 
reviews that found a strong association between severe anaemia and maternal mortality [4, 
5]. In a review of anaemia in pregnancy in developing countries, van den Broek [6] 
concluded that estimates of maternal mortality from anaemia range from 34 per 100,000 live 
births in Nigeria to as high as 194 per 100,000 in Pakistan and that in combination with 
obstetric haemorrhage, anaemia is estimated to be responsible for 17 - 46% of cases of 
maternal deaths. During pregnancy, low haemoglobin levels, indicative of moderate 
(between 7.0 and 9.0 g/dL) or severe (less than 7.0 g/dL) anaemia, are associated with 
increased risk of maternal and child mortality and infectious diseases [7].  
Cham et al [8] in determining the causes and contributing factors to maternal deaths in rural 
Gambia showed that anaemia was the leading cause of death followed by haemorrhage.  In 
a retrospective study of maternal deaths in a referral hospital in The Gambia, a four-fold 
increase in the proportion of maternal deaths due to anaemia was recorded between 1991 - 
1992 and 2001 – 2001 (8%-32% respectively) and a six fold increase of maternal mortality 
ratio due to anaemia (P = 0.000003) between 2001 - 2002 [9]. 
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However, according to Greenwood et al [10], although maternal mortality was found to be 
very high (22 per 1000 live births), the major contributing factors to maternal mortality in The 
Gambia were post-partum haemorrhage and infections, early or late pregnancies (under 20 
or over 40 years), multiple pregnancies and obstructed labour.  Other indirect contributing 
factors included anaemia, low standard of health care for obstetric referrals, delayed 
decision making for referral and lack of transport [10, 11]. Post-partum haemorrhage being 
the major cause of maternal deaths has also been shown in many studies together with 
obstructed labour, post-partum sepsis, eclampsia and unsafe abortion. [5, 12-14]. 
The contribution of anaemia as one of the major indirect causes of maternal mortality has 
been demonstrated in many studies [11, 13, 14].  Whereas a strong association has been 
shown between severe anaemia and maternal mortality, the same cannot be said for mild or 
moderate anaemia where the relative risk associated with moderate anaemia (Hb 40-80 g/L) 
is 1.35 [95% CI: 0.92-2.00] and that for severe anaemia (< 47 g/L) is 3.51 [95% CI: 2.05-
6.00] [4]. 
Urging on the side of caution in the interpretation of the data on maternal anaemia and 
maternal mortality, Allen [15] is quoted thus, “some data show an association between a 
higher risk of maternal mortality and severe anemia. Such data were predominantly 
retrospective observations of an association between maternal hemoglobin concentrations 
at, or close to, delivery and subsequent mortality. Such data do not prove that maternal 
anaemia causes higher mortality because both the anaemia and subsequent mortality could 
be caused by some other condition. No prospective studies have proven that anemia per-se 
increases the risk of maternal mortality, and there is inadequate information on an 
established hemoglobin concentration below which the risk of mortality increases”. 
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2.2 Maternal anaemia and iron status of the foetus and of infants 
 
There has been mounting evidence to indicate that maternal iron deficiency in pregnancy 
reduces foetal (and hence infant) iron store perhaps well into the first year of life and that this 
deserves further exploration because of the tendency of infants developing iron deficiency 
anaemia coupled with the documented adverse consequences of this condition on infant 
development [15].  
Several studies have demonstrated that haemoglobin, serum iron, transferrin saturation and 
ferritin are significantly lower in the cord blood of anaemic women suggesting that iron 
supply to the foetus is reduced in maternal anaemia.  This further suggests that maternal 
anaemia adversely affects the iron status including iron stores of the newborn [16-24]. 
Even moderate or mild iron deficiency in mothers has been shown to contribute to lower iron 
reserves, if not frank iron depletion in the foetus [25-27] and that even non-anaemic iron 
deficient mothers may affect the iron status in their babies and predispose them to iron 
deficiency [28]. 
In a study of 617 pregnant women and their children in Benin, the relationship of newborn 
anaemia to maternal anaemia had an odds ratio equivalent to 1.8 (CI = 1.2-2.5) [29] and 
Faber et al [30] found that the child of an anaemic mother had a relative risk of 1.63 of also 
being anaemic.  Meinzen-Derr et al [31] also found that maternal anaemia was 
independently associated with a 3 fold increased risk of infant anaemia. In a study in Malawi, 
Brabin et al [32] found that where foetal anaemia occurred in 23.4% of babies, the factors 
associated with foetal anaemia were among other things; maternal Hb at delivery < 8 g/dL 
(AOR 1.61, 1.10-2.42) or <11 g/dl (AOR 1.60, 1.10-2.31) (AOR= adjusted odds ratio).  They 
also noted that up to 60% of cases of foetal anaemia were directly attributable to maternal 
anaemia, Figure 1. 
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Figure 1: Estimates of population-atributable risk of fetal anaemia in a highly 
malarious area in relation to maternal anaemia (Hb <8g/dL; --------- upper 95% CI, 
········· lower 95% CI,          PAR for anaemia (Hb <8g/dL). 
 
 
Babies born to mothers with low haemoglobin are born with less total body iron (TBI) 
resulting in a substantially greater risk of anaemia from 3 to 12 months of age [33].  For 
serum ferritin concentration of newborn babies born to mothers with low serum ferritin at 
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term, their serum ferritin levels have been found to be significantly lower than those born to 
mothers with normal ferritin concentration and the difference between the two groups of 
infants persisted up to 6 months of age [34].  Similar findings have also been illustrated by 
Savoie Rioux [27], Colomer et al [35], Kilbride et al [36] showing a relationship between iron 
deficiency of the mother at delivery and the development of iron deficient infants up to age 
12 months which may not have been detected at birth.  However, Colomer et al [35] found 
no association between the infants’ haemoglobin at 18 months and maternal anaemia. 
The linear relationship between cord iron parameters (haemoglobin, serum ferritin, 
transferrin saturation) and maternal haemoglobin and serum ferritin, tends to indicate that 
the foetus extracted iron in amounts proportional to levels available in the mother leading to 
mothers with moderate to severe anaemia having significantly lower cord serum ferritin 
levels [24] suggesting a placenta iron threshold, limiting iron acquisition by the foetuses of 
women with severe iron deficiency [37]. 
Haemoglobin concentration [38, 39] and mean corpuscular volume  [38] were significantly 
lower in babies born to iron deficient mothers than in babies born to iron sufficient mothers. 
Savoie Rioux [27] found a positive association between mother’s haemoglobin and 
haematocrit during her third trimester and her infant’s haemoglobin and haematocrit levels 
even at 9 months of age. Sweet et al [40] found that although maternal iron depletion was 
associated with reduced foetal iron stores because it was associated with decreased cord 
blood ferritin and haemoglobin, there was no change in free iron availability. 
A few studies that found a relationship of other indices such as serum ferritin have 
questioned the correlation between maternal haemoglobin concentration and cord venous 
haemoglobin levels where Altinkaynak et al [41], Erdem et al [42], Goonewardene Liyanage 
[43], Mowafy Youssef [44] found no such correlation.  Similarly, Shyamala et al [45] found no 
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significant difference in mean haemoglobin concentration in neonates born to anaemic 
mothers compared to those born to non-anaemic mothers. 
On the other hand, several investigators have found that the iron status of pregnant women 
with iron deficiency or mild anaemia does not seem to have a significant impact on the iron 
levels found in their children [46-48].  When haemoglobin, the most widely used index for 
assessment of anaemia [49] is used and levels assessed in maternal and cord blood, no 
significant relationship is found [50-53].  Redd et al [54] observed that neither the mothers 
haematocrit at enrolment or at delivery was associated with having a low haematocrit in 
infants even 3 months after birth and Ogunbode [55] even observed that babies delivered by 
anaemic women at term were shown to have haematocrit levels that were actually in the 
normally acceptable range.  In fact, severe maternal anaemia has been occasionally found 
to be associated with higher haemoglobin and ferritin values in the foetus [56], and higher 
serum iron levels in cord blood [57]. 
Serum ferritin levels have been noted as being by far the best indicator of iron store status in 
the absence of acute or chronic inflammation [58] and have been widely used in the 
assessment of iron deficiency anaemia.  However, Gebre-Medhin Birgegard [59] in looking 
at serum ferritin levels of Ethiopian and Swedish mothers and their newborn infants found no 
correlation between maternal and cord blood ferritin. On the other hand, MacPhail et al [60] 
only found a weak correlation between maternal and cord serum ferritin concentration in 103 
pregnant women and their normal term offspring in South Africa.   In the case of iron 
supplementation, no significant difference was observed for serum ferritin of the newborn 
infants whether mothers received supplementation or not [61, 62] but Preziosi et al [61] 
noted that 3 months after delivery, serum ferritin concentrations were higher in infants of 
women supplemented with iron. 
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Polat et al [63] found that although soluble transferrin receptor (sTfR) levels of mothers with 
iron deficiency were higher than those of mothers having no iron deficiency (P=0.009) there 
was no difference in the levels of sTfR between newborns of both groups of mothers 
(P=0.790). 
Mothers with a reduced store of iron (serum ferritin) at term can still manage to provide 
significant iron for the foetus [64] and the foetus continues to take up iron from the mother 
until delivery [65].  However, Balai et al [66] suggested that even though there is a selective 
intake of iron by the foetus in anaemic women to a ratio of maternal versus neonatal of 
1:2.02 in an anaemic group as compared to 1:1.6 in the non-anaemic group, the selective 
intake by the foetus cannot prevent the development of anaemia in the newborn. Recent 
evidence from our group also shows that even in conditions of low maternal iron and the 
absence of zinc supplementation, the placenta upregulates the gene expression of iron and 
zinc uptake proteins, presumably to meet foetal demand in the face of low maternal supply 
[67] 
Nonetheless, Ervasti et al [68] showed that in well-nourished maternal populations, lower 
maternal iron status did not affect iron accumulation on the foetal side and Harthoorn-
Lasthuizen et al [69] concluded that foetal iron supply is not negatively influenced by iron 
deficient erythropoiesis in the mother. 
Breast milk iron content has been found to be significantly reduced in severely anaemic 
mothers but not in those with mild-to-moderate anaemia [70].  Breastmilk micronutrients 
including iron were observed to be significantly reduced in anaemic mothers [20].  However, 
mothers’ haemoglobin and iron status have been found to have no relationship to breastmilk 
iron [71] and lactoferrin [72]. Baykan et al [73] even suggested that giving maternal iron 
supplementation during the first four months of lactation had no effect on serum iron and 
serum ferritin levels of mothers and infants, albeit the follow-up period was short in the study. 
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Delayed cord clamping in full term neonates for minimum of two minutes following birth is 
beneficial to the newborn extending in to infancy by improving iron status [74, 75].  This may 
lead to a clinically important reduction of the risk of anaemia in the newborn [74]. However, 
delayed cord clamping has been found to also lead to the increased risk of benign 
polycythemia [74] and jaundice requiring phototherapy.  It is suggested that waiting until the 
umbilical cord stops pulsating is a feasible, low-cost intervention that can reduce anaemia in 
infants in developing countries [76]. 
In summary, it appears that there is a relationship between maternal anaemia and the iron 
status of their infants with anaemic mothers giving birth to babies with low iron stores.  
However, it should be noted that the measurement of haemoglobin alone may not 
necessarily lead to this conclusion as numerous studies found no correlation between 
maternal haemoglobin and cord or infant haemoglobin levels. It looks likely that where 
maternal iron stores are low, the newborns’ iron endowment is affected.  It is worth noting 
that different studies used different iron status markers and this makes it difficult to compare 
the results across studies.   
 
2.3  Maternal anaemia and birth outcome: focus on low birth weight (LBW) 
 
It has been shown in the West African state of Benin, that even with malaria and helminth 
prophylaxis, as well as iron and folic acid supplementation, prevalence of anaemia 
throughout pregnancy remained very high [77].  Severe anaemia was found to be associated 
with a higher risk of LBW.  However, the adverse impact of moderate to mild anaemia was 
unclear [77].  There is evidence that maternal haemoglobin levels below 9.5 g/dL before or 
during the second trimester of gestation are associated with increased risk of giving birth to a 
low birthweight infant and with premature delivery [7]. However, low birth weight and preterm 
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delivery have been found to be related to pregnancy haemoglobin levels in a ‘U’ shape 
manner where severe anaemia and high haemoglobin concentration are both associated 
with increased risk of LBW and preterm deliveries [78-81]. 
Scanlon et al [82] noted that “an elevated Hb level (>14.4g/dL) is an indicator of possible 
pregnancy complication associated with poor plasma volume expansion (PVE) and should 
not be mistaken for good iron status”.  Haemoglobin levels are expected to rise and fall at 
different stages of pregnancy due to plasma volume increase to meet the greater circulatory 
needs of the placenta and maternal organs with an average plasma volume increase of 
about 45% [83, 84].  The magnitude of the fall in haemoglobin concentration has been found 
to be related to birth weight and the failure of the haemoglobin concentration to fall below 
10.5 g/dL indicates an increased risk of LBW and preterm delivery as seen in Figures 2 and 
3, respectively [80, 85]. 
 
Figure 2: Incidence of low birth weight (<2500 g) by haemoglobin concentration (g/L) 
(data for white women only). 
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Figure 3: Adjusted odds ratios* (95% confidence intervals) for low birth weight (<2500 
g) and preterm birth (<37 completed weeks). 
Source: Adapted from: Steer et al [80].  
Maximum mean birth weight has been observed in the haemoglobin category of 9.6-10.5 
g/dl and therefore the least incidence of LBW.  Mean birth weight fell with both increasing 
and decreasing haemoglobin values and consequently an increased incidence of LBW [80, 
86].  
Rasmussen [79] in a review of the literature concluded that; “in populations with low rates of 
iron or folate deficiency among non-pregnant women, the primary cause of anaemia is likely 
to be PVE, and this anaemia is not associated with negative birth outcomes.  However, 
maternal haemoglobin values during pregnancy are associated with birth weight and preterm 
birth in a ‘U’shape relationship with higher rates of babies who are small, early or both at a 
low or high concentrations of maternal haemoglobin.  A similar ‘U’ shape relationship is likely 
to be present between maternal haemoglobin concentration and neonatal and perinatal 
mortality but data for this remain insufficient”. 
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2.4 Current methods of assessing iron deficiency (ID) and iron deficiency anaemia 
(IDA) and their problems 
 
The most significant contributor to the onset of anaemia is iron deficiency and consequently 
iron deficiency anaemia and the two are often used synonymously [1].  Iron deficiency is 
defined as a condition in which there are no mobilisable iron stores and signs of a 
compromised supply of iron to tissues including the erythron are noted [87]. Generally, it is 
assumed that iron deficiency is the most frequent single cause of anaemia and that 50% of 
anaemia is due to iron deficiency [88-90]. WHO estimates that IDA affects almost half of the 
world’s pre-school children and pregnant women with prevalence of over 65% in Africa and 
Asia, and, as discussed above, that it causes (directly or indirectly) one fourth of all maternal 
deaths [2].  Despite iron deficiency with or without anaemia having important consequences 
for human health and child development, there has been an absence of international 
agreement on how best to assess the iron status of populations [91]. 
Although accurate assessment of iron status is difficult, several well-established tests for iron 
status determination are available [6, 49].  However, there is no single standard test to 
assess iron deficiency without anaemia [49] (Table 2).  The use of multiple tests only 
partially overcomes the limitations of the individual tests [92] and conducting several tests 
together to determine iron status is costly and inconvenient and therefore not an option in 
resource poor settings [49, 93]. 
 The definitive method of assessing iron stores in pregnancy is still by examination of a 
stained bone marrow preparation [6] but the procedure is invasive [94] and traumatic  [91].   
Serum ferritin (SF) is one of the few biochemical indices of which low levels reflect depleted 
iron stores [49] and it has been found to be a significant and convenient predictor of iron 
deficiency anaemia [94, 95].  However, ferritin is raised by infection and inflammation and 
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thus has very high false negative rates in least developed countries as it is highly specific but 
has low sensitivity [96]. 
Zinc protoporphyrin (ZnPP) levels can be used as an indicator for lack of iron to the 
developing red blood cells [91].  In general, elevated levels correlate well with low serum 
ferritin and can serve to screen for moderate iron deficiency without anaemia [97].  However, 
levels can be affected by infection and inflammation [94]. 
The concentration of soluble transferrin receptors (sTfR) provides a semi-quantitative 
measure of the severity of iron deficiency even in the presence of inflammatory disorders 
[91] and it shows a sensitive response during the early development of iron deficiency 
including mild tissue iron deficiency [98].  However, sTfR may be elevated when there is 
increased red cell production, turnover or both, and there is a lack of uniform standards and 
agreed references for its measurement [49]. 
The use of the sTfR/LogSF ratio for estimation of iron stores has been demonstrated in 
healthy adults to be a good measure of iron status [93].  Although the method has been 
validated, there is a lack of standardisation in the assay ranges, unit of measurement and 
reference samples.  The serum ferritin component is also influenced by infection and chronic 
disease [91].   
Serum iron, total iron binding capacity (TIBC) and transferrin indices are also often used but 
none of these are very reliable indicators because they show marked individual variations, 
are affected by recent iron ingestion and are also sensitive to infection [6].  Just like serum 
iron, transferrin saturation (TSAT) is also used for estimation of chronic iron estimation but 
lacked specificity as any alteration in plasma iron concentration will alter its level [91].  
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Table 2: Limitation of current methods of assessing IDA 
 
The recently discovered hormone, hepcidin (Section 2.5) is the master regulator of iron 
metabolism and there is now a considerable enthusiasm in the potential role of plasma and 
urinary hepcidin concentration in the screening of iron deficiency [94, 99].  
 
2.5 Potential for hepcidin to be an improved index of ‘safe and ready to receive’ 
iron: 
 
Hepcidin is a peptide hormone that has been shown recently to be the master regulator of 
iron absorption and distribution in humans [100-103]. Hepcidin controls iron homeostasis by 
inhibiting dietary iron absorption, release of iron in the macrophages and reducing iron flow 
to the erythron [102, 104-107] (Figure 4).  Hepcidin binds to the iron exporter ferroportin 
inducing its internalisation and degradation [108] (Figure 5). Ferroportin is the sole known 
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iron exporter from cells [105] and is also the only mammalian iron exporter identified to date 
for materno-fetal iron transfer [109]. Levels are known to be reduced by hypoxia and iron 
deficiency [103] and increased by iron sufficiency or overload and infections [110-112]. 
Schulze et al [113] provided strong evidence that iron status influences hepcidin 
concentrations among pregnant Bangladeshi women indicating an insight in to the role of 
hepcidin in iron deficiency associated with pregnancy.  The potential for hepcidin as a 
superior marker for iron deficiency has been highlighted in many recent studies [114-118]. 
Pasricha et al [117] in evaluating hepcidin concentration as a test for iron deficiency in a 
large group of blood donors in a high risk anaemia area found that hepcidin shows a 
considerable promise as a diagnostic test for iron deficiency and appears to perform at least 
as well as available iron indices such as sTfR and reticulocyte haemoglobin.  The team 
indicated that for a diagnosis of iron deficiency defined by a sTfR/log ferritin index, hepcidin 
less than 18 ng/ml has a sensitivity of 79.2% and a specificity of 85.6%. “On-going analysis 
within our group is yielding an even better performance among rural Gambian children, 
suggesting that hepcidin will be a superior index in scenarios where infections are common” 
[119] 
A few studies have noted that over the course of a malaria season, hepcidin integrates 
signals arising from parasitaemia, inflammation and anaemia [96, 120]. The fact that 
hepcidin plays a crucial role in the above signals and acts both as a reporter of iron status 
and an effector of iron absorption, distribution and metabolism suggests it may be the ideal 
index for iron deficiency and form the basis of a point-of-care-diagnostic for iron deficiency 
for at-risk population groups in developing countries [120]. 
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Figure 4: Hepcidin regulates intestinal iron absorption, iron recycling by 
macrophages, and iron release from hepatic stores. 
Source: Adapted from Drakesmith Prentice [121] 
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Figure 5: Hepcidin regulates ferroportin expression on the basolateral membrane of 
entrocytes. Left: irron deficiency, with hepcidin secretion suppressed and ferroportin 
strongly expressed on the basolateral membrane, iron absorption is maximal. Right: 
iron excess. The liver secretes hepcidin, which interacts with ferroportin molecules 
on the basolateral membrane, causing ferroportin to be endocytosed and degraded. 
Iron export from enterocytes is decreased, and the cells fill with iron. Eventually, iron-
filled enterocytes will be shed into the lumen of the intestine. Adapted from: Ganz 
Nemeth [105]. 
 
2.6 Hepcidin and Pregnancy  
 
A review of the literature on hepcidin in pregnancy revealed very little published data. 
However,  Rehu et al [122] concluded that hepcidin concentration has been observed to be 
low at term during pregnancy allowing for the increased availability of iron to the fetus and 
that maternal and cord blood hepcidin are independently associated with maternal and cord 
blood iron status, respectively.  Maternal serum hepcidin and maternal/neonatal iron status 
are thought to play a role in placental uptake of both haem and non-haem iron with a greater 
percentage of haem iron present in the neonates [123].  
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On the other hand, urinary hepcidin is not found to be significantly related to haemoglobin, 
erythropoietin or C-reactive protein [113, 124], although, Schulze et al [113] found urinary 
hepcidin among pregnant women in rural Bangladesh to be related to iron status and alpha-
1 acid glycoprotein (AGP). 
An apparent ineffectiveness of hepcidin has been highlighted in two studies; in one of the 
studies, neither placental infection nor maternal anaemia were related to maternal or cord 
blood hepcidin concentrations and iron status [48].  In the other study, plasma iron 
concentrations were found to be increased despite high hepcidin concentration in 
preeclampsia and this might indicate a resistance to iron decreasing action of hepcidin [125]. 
 
2.7 Need for a better point-of-care (PoC) diagnostic 
 
Iron status can be considered as a continuum from iron deficiency; iron deficiency with no 
anaemia; iron deficiency with anaemia; to normal status with varying amounts of stored iron 
and finally to iron overload which can cause organ damage [87] or in the case of oral 
supplementation may lead to serious adverse consequences in infectious environments 
[126].  Since iron deficiency anaemia is a common cause of maternal anaemia, iron 
supplementation is a common practice to reduce the incidence of maternal anaemia [127, 
128]. 
Placebo controlled studies of iron supplementation during gestation showed that women 
taking placebo have lower iron status (lower serum ferritin and haemoglobin) compared to 
women taking iron supplements and that differences in iron status persist for many months 
after delivery [129].  The studies also showed that a significant fraction of the women on 
placebo, developed iron deficiency and iron deficiency anaemia [129, 130]. In The Gambia, 
a double blind placebo controlled community based oral iron supplementation trial (200 mg 
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ferrous sulphate) showed that iron supplementation reduced the prevalence of anaemia and 
iron deficiency [131].    
Hence the World Health Organisation recommends universal iron supplementation with all 
pregnant women to be given 60 mg iron and 400 ug folic acid daily [49]. which was later 
updated in 2012 [132] recommending that pregnant women should be supplemented  with 
30 - 60 mg elemental iron throughout pregnancy, starting as early in pregnancy as possible, 
with a preferred daily dose of 60 mg of elemental iron in settings where anaemia in pregnant 
women is a severe public health problem (prevalence of 40% or higher). 
However, a recent review has shown that pregnant women who received daily iron and folic 
acid supplementation are at a greater risk of haemoconcentration (haemoglobin greater than 
130 g/L) in the second and third trimester of pregnancy than those who received no 
treatment or placebo [130].  Although the effect of the haemoconcentration in the above 
review was uncertain, Ziaei et al [133] in a randomised placebo-controlled trial of over 700 
participants (pregnant women) who took 50 mg elemental iron as ferrous sulphate daily 
throughout pregnancy found that small-for-gestational-age birth rate and the number of 
women with hypertension disorders increased significantly.  They concluded that routine iron 
supplementation in non-anaemic women is not rational and may be harmful.  Recently, two 
hazardous complications of pregnancy; gestational diabetes mellitus and preeclampsia have 
been recognized to be associated with elevated body iron levels [134].  Iron supplementation 
has also been found to be associated with glucose impairment and hypertension [135]. 
Recent studies and reviews have shown that pregnant women who are anaemic and iron 
deficient may be protected from malaria [136, 137]. With the use of flow cytometry our group 
demonstrated that P. falciparum erythrocytic stage growth in vitro is reduced in anaemic 
pregnant Gambian women at baseline, but increases during supplementation (Figure 6) 
[138].  It has been noted that although there has been significant reduction of malaria in 
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malaria endemic areas, anaemia still causes a high burden among pregnant women [139, 
140]. 
Nonetheless, iron supplementation programmes for pregnant women are currently being 
implemented in 90 of the 112 countries that reported to WHO in 1992.  However, most of 
these programmes are neither systematically implemented nor well monitored or evaluated 
[49]. 
 
 
 
 
Figure 6: Malaria susceptibility increases transiently during iron supplememtation and 
pregnant women receiving iron supplements have increased numbers of young RBCs 
(Goheen et al 2017) [138].   
 
It is believed by many that one of the reasons national iron supplementation programmes 
have failed is because of women’s non-compliance with taking iron supplements daily 
because of gastrointestinal upsets [141, 142] and other side effects [130, 141-143] that 
sometimes occur when taking iron. Despite the importance of side effects, recent studies 
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have shown that side effects have a limited influence on compliance [129, 144].  Other 
issues found to be more important than side effects affecting compliance include: inadequate 
supplies, inadequate counseling [142], poor access to prenatal services, beliefs against 
consuming the tablets, fears that consuming too much may cause too much blood or a big 
baby and make delivery difficult [3].   
Much has been made of iron dosage and how much iron is adequate during pregnancy as a 
supplement.  Milman [129] in a review of iron prophylaxis in pregnancy noted that “there 
used to be a tradition of recommending high doses of iron supplements of 100 - 200 mg of 
ferrous iron daily in pregnancy where a daily dose of 100 mg will induce a maximum rise in 
haemoglobin concentration and a dose of 200 mg of ferrous iron increases serum ferritin and 
haemoglobin at term to the same or even higher level as in non-pregnant women.  It is also 
noted that 66 mg ferrous iron daily from 18 weeks gestation can prevent iron deficiency 
anaemia in all pregnant women”. 
However, other studies found that 40 mg ferrous iron daily was adequate to prevent iron 
deficiency (France); a daily dose of 27 mg had a favourable influence in pregnant Norwegian 
women; in Australia a daily dose of 20 mg ferrous iron from 20 weeks gestation reduced the 
frequency of iron deficiency and iron deficiency anaemia at delivery; and in Denmark, a daily 
dose of 40 mg ferrous iron appeared to be adequate for preventing iron deficiency anaemia 
for 95% of the women [129].   In settings where prevalence of anaemia is lower than 20%, 
WHO has recommended the intermittent use of iron and folic acid supplements (one 
supplement of 120 mg iron and 2800 ug folic acid once a week) for non-anaemic pregnant 
women to prevent anaemia and improve gestational outcomes [145]. However, Moretti et al 
(2015) [146]showed that Iron supplementation at doses of 60 mg Fe as FeSO4 or higher 
increase hepcidin for up to 24 hours and are associated with lower iron absorption on the 
following day. Providing lower dosages (40-80 mgFe) and avoiding twice-daily dosing 
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maximise fractional absorption. The duration of the hepcidin response supports alternate day 
supplementation.  
 There is now some evidence that smaller doses of 30 mg iron daily could achieve similar 
results as the daily 60 mg iron [49].   In a Cochrane review of the treatments of iron 
deficiency anaemia in pregnancy, Reveiz et al [147] as part of their conclusion indicate that 
daily low dose iron supplementation might be effective at treating anaemia in pregnancy with 
less gastrointestinal side effects compared with higher doses. WHO therefore recommended 
in 2012 that for countries exceeding 40% anaemia prevalence, daily supplementation with 
30 - 60 mg elemental iron (as ferrous salt) be given throughout pregnancy, starting as early 
in pregnancy as possible, with a preferred daily dose of 60 mg of elemental iron in settings 
where anaemia in pregnant women is a severe public health problem [132]. 
 
2.8 Use of multiple micronutrient supplements 
 
UNIMMAP formulation has been used in other pregnancy trials in developing countries with 
good patient compliance, acceptability and favourable outcomes.  Micronutrient supplements 
with three or more micronutrients is associated with a 39% reduction in maternal anaemia 
compared with placebo or with two micronutrients or fewer (relative risk 0·61, 95% CI 0·52-
0·71). Multiple micronutrient supplementation is also known to result in a decrease in the risk 
of low-birth weight babies (0·83, 0·76-0·91) and small-for-gestational-age babies (0·92, 
0·86-0·99) [148]. In a 2017 Cochrane review, Haider and Bhutta [149] concluded that, in 
comparison with iron, with and without folic acid, daily multiple micronutrient 
supplementation during pregnancy reduced the risk for low birthweight and small-for-
gestational-age births in LMICs.   
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Smith et al [150] identified several subgroups of mothers that might experience greater 
benefits from antenatal multiple micronutrient supplementation than from iron-folic acid 
supplementation alone. In anaemic women, multiple micronutrient supplementation resulted 
in greater reductions in the risk of low birthweight by19%, small-for-gestational-age births by 
8%, and infant mortality at 6 months of age by 29% than in non-anaemic women. In 
underweight women (BMI <18·5 kg/m2), multiple micronutrient supplementation reduced the 
risk of preterm birth by 16%. Furthermore, initiation of multiple micronutrient supplementation 
before 20 weeks’ gestation decreased the risk of preterm birth by11% and high adherence to 
regimen (≥95%) decreased the risk of infant mortality by15%.  
In summary, although iron supplementation has been recommended in the management of 
iron deficiency and iron deficiency anaemia, iron supplementation in developed countries still 
remains controversial and hence supplementation should include screening with ferritin in 
early pregnancy in order to identify women who can manage without prophylactic iron [151]. 
In developing countries, Brabin et al [152] revealed there is in vitro evidence that iron 
availability influences severity and chronicity of infections that cause such outcomes as 
stillbirth, preterm birth and congenital infection and that although reducing iron deficiency 
anaemia among women is beneficial and should improve the iron stores of babies, caution 
with maternal iron supplementation is desired in iron-replete women who have high infection 
exposure to avoid iron intervention strategies that result in detrimental birth outcomes for 
some groups of women. 
However, iron supplementation combined with other measures depending on the aetiology 
of the anaemia remains a viable option in combating anaemia and hence the assessment of 
iron status at the point of care will help in determining who should receive iron and when it is 
safe to receive on the day and point where the pregnant woman is receiving antenatal care. 
Therefore, in an effort to contribute towards the reduction of maternal morbidity and mortality 
due to anaemia and iron deficiency, we conceived the idea of testing the hypothesis that a 
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screen-and-treat approach to iron supplementation below the pre-determined hepcidin cut-
off value (<2.5 µg/L), is non-inferior to the reference arm (WHO-recommended universal iron 
supplementation of 60 mg iron) in preventing anaemia and iron deficiency at a lower dose 
and hence improve safety and tolerability after 12 weeks intervention with haemoglobin 
concentration as the primary endpoint. Figure 7 shows the study location in rural Gambia. 
 
Figure 7: Study location 
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Research in Context  
 
Evidence before this study  
Based upon regularly updated meta-analyses, the World Health Organisation (WHO) 
recommends that pregnant women should take supplements containing 30 to 60mg 
elemental iron and 400μg folic acid daily to prevent maternal anaemia, puerperal sepsis, low 
birthweight and pre-term birth. If daily supplementation is not acceptable due to side effects, 
weekly supplementation with 120mg iron and 2800μg folic acid is an acceptable alternative 
in areas where the prevalence of anaemia is less than 20%.   
  
Side effects (including constipation, black stool, dizziness, nausea, vomiting and epigastric 
discomfort) are frequently reported and contribute to poor adherence. These might be 
caused by unabsorbed iron passing to the large intestine and colon and causing oxidative 
stress and/or shifts in the gut microbiome (dysbiosis). There are additional concerns that iron 
might predispose to gestational diabetes, pre-eclampsia and infections, especially malaria 
where it is known that anaemia and iron deficiency protect against P falciparum infections in 
pregnancy.  
  
We reasoned that a screen-and-treat approach to combatting anaemia in pregnancy would 
be advantageous if it could achieve equivalent or better efficacy at a lower overall dose of 
iron and with fewer side effects. We determined a threshold for the iron-regulatory hormone 
hepcidin that would indicate ‘ready-and-’ to receive iron and used this, in a double-blind 
randomised trial, to test two hepcidin-guided screen-and-treat approaches against the 
standard 60mg per day regime. There have been no prior studies of hepcidin-guided 
antenatal iron supplementation and no other similar trials have been registered.  
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Added value of this study  
With the primary outcome of maternal haemoglobin, we demonstrated that a weekly screen-
and-treat approach administering 60mg/d iron to women whose hepcidin indicated ready-
and-safe to receive iron was non-inferior to the 60mg/d standard of care using a pre-defined 
non-inferiority margin of -5.0g/L haemoglobin. A screen-and-treat approach using 30mg/d 
was not conclusively non-inferior. Secondary outcomes of prevalence of anaemia and iron 
deficiency showed clear evidence of inferiority in both screen-and-treat groups at both dose 
levels. There was a decreased frequency of iron administration in the screen-and-treat 
groups relative to the control group. Side effects were fewer in the 30mg/d screen-and-treat 
arm, but there was no substantive evidence that the screen-and-treat regimens were likely to 
be safer according to adverse events or ex vivo tests of P falciparum growth in red blood 
cells or sentinel bacterial growth in plasma. Compared to baseline plasma, the growth of all 
pathogens was markedly higher in plasma taken after commencement of iron 
supplementation in all trial arms.  
  
Implications of all the available evidence  
We were unable to demonstrate any clear advantages of a hepcidin-guided screen-and-treat 
approach to maternal iron supplementation over the current WHO-recommended standard of 
care. These data, together with the available evidence suggests that that efforts should be 
directed towards developing low-cost iron supplements with better side effect profiles to help 
overcome the poor adherence that currently undermines antenatal iron supplementation 
programmes.
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Abstract: 
 
BACKGROUND: WHO recommends daily iron supplementation for pregnant women but 
adherence is limited by side-effects, effectiveness is low, and there are concerns around 
possible harm. The iron-regulatory hormone, hepcidin, signals ‘ready-and-safe’ to receive 
iron. We tested whether a hepcidin-guided screen-and-treat (S&T) approach to combat iron 
deficiency anaemia (IDA) could achieve equivalent efficacy to universal administration but 
with lower exposure to iron. 
METHODS: We conducted a 3-arm randomised-controlled double-blind trial in rural Gambia 
to assess non-inferiority of two S&T interventions versus WHO standard of care (enrolment 
June 2014 to March 2016). Participants received daily, either: a) UNU/UNICEF/WHO 
international multiple-micronutrient preparation (UNIMMAP) containing 60mg iron (reference 
group, REF); b) UNIMMAP containing 60mg iron for 7d if weekly hepcidin was <2·5µg/L or 
UNIMMAP without iron if hepcidin was ≥2·5 µg/L (S&T60); or c): as b), but with 30mg iron 
(S&T30). We randomised 498 pregnant women (18-45y) recruited between 14-22wks 
gestation using a block design stratified by haemoglobin and stage of gestation (REF n=167; 
S&T60 n=166; S&T30 n=165). Participants and investigators were blinded. Primary endpoint 
was haemoglobin at D84 with a non-inferiority margin of -5·0g/L. Secondary outcomes were 
anaemia, iron deficiency (ID), IDA, adherence and side-effects, and ex vivo assays of 
malaria and sentinel bacterial growth. Trial registration was ISRCTN21955180. 
FINDINGS: In per protocol analysis of the primary outcome the screen-and-treat approaches 
did not exceed the preset non-inferiority margin of -5·0g/L (endpoint haemoglobin: S&T60 -
2·2g/L, 95%CI:-4·6,0·1g/L (n=133); S&T30 -2·7g/L, 95%CI:-5·0,-0·5g/L (n=147) versus REF 
(n=140)). Intention-to-treat analysis yielded similar results (endpoint haemoglobin: S&T60 -
1·3g/L, 95%CI:-3·5,1·0g/L (n=164); S&T30 -2·9g/L, 95%CI:-5·1,-0·7g/L (n=165) versus REF 
(n=165). For secondary outcomes at D84, anaemia (haemoglobin <110g/L)   was more 
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common in the S&T groups (S&T60=57·3%, S&T30=59·3% vs REF=45·3%) and ID and IDA 
were also more common in the S&T groups assessed using ferritin, transferrin saturation, 
soluble transferrin receptor or hepcidin. S&T60 received 54% and S&T30 74% less iron than 
REF. Adherence, reported side effects and adverse events were similar between groups. Ex 
vivo tests of malarial growth in erythrocytes and bacterial growth in serum were elevated 
after iron but did not differ by treatment. 
INTERPRETATION: The hepcidin-guided screen-and-treat approaches were less 
efficacious in combatting ID and IDA than universal daily iron supplementation and had no 
advantages in terms of adherence, side effects or safety outcomes. Our results suggest that 
the current WHO policy for iron administration to pregnant women should remain 
unchanged. 
FUNDING: Bill & Melinda Gates Foundation and UK Medical Research Council. 
 
Keywords: Pregnancy, anaemia, iron deficiency, iron supplementation, hepcidin, screen-
and-treat, UNIMMAP, adverse effects.
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INTRODUCTION 
Iron deficiency and its associated anaemia (IDA) is the most prevalent micronutrient 
deficiency worldwide affecting an estimated 1·24billion people.1 It is the leading cause of 
years lived with disability in most of sub-Saharan Africa and many parts of Asia.1 WHO 
recommends universal daily iron and folic acid supplementation (IFAS) in pregnancy2 based 
on Cochrane evidence that it provides maternal and neonatal health benefits.3 
Recommended dosage ranges between 30-60mg elemental iron daily with a preferred dose 
of 60mg in countries where anaemia prevalence exceed 40%.2 In low and middle-income 
countries, IFAS has greater benefits for iron-deficient women4 and is increasingly being 
combined in multiple micronutrient formulations.5 However, even when supplements are 
made available, adherence is low4-7 due in large part to gastrointestinal side effects 
(constipation, nausea, vomiting, black stools and epigastric discomfort).8,9 This led WHO to 
also recommend intermittent supplementation ‘if daily iron is not acceptable due to side 
effects’.10,11 There are also concerns that iron supplementation can predispose to 
haemoconcentration3 and gestational diabetes.12 In low income settings, there is the 
additional possibility that iron supplementation might increase gastro-intestinal and other 
infections,4 especially malaria. Anaemia and low iron status are associated with protection 
against falciparum malaria in pregnant women13,14 and there are clear pathways by which 
iron administration abrogates this protection.15 Thus, lowering the dose of supplemental iron 
could be beneficial, if it could be achieved without compromising efficacy. 
 
We reasoned that hepcidin, the hepatic iron-regulatory peptide that acts as a master 
regulator of iron metabolism, could signal when women are ‘ready-and-safe’ to receive iron, 
and hence could form the basis of a screen-and-treat IFAS regime. Hepcidin is the 
homeostatic regulator of body iron absorption, distribution and metabolism.16 Circulating 
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hepcidin is suppressed during iron deficiency, anaemia, and increased erythropoiesis, and 
increased by high serum and hepatic iron, and during infection and inflammation.17 By 
integrating these competing signals a low hepcidin level indicates when the body is iron 
deficient18,19 and will efficiently absorb iron.20 Conversely, raised hepcidin would block 
duodenal iron absorption thereby rendering supplementation ineffective and exposing the 
gut microbiota to unnecessary iron that may cause dysbiosis and side effects.21 
 
We hypothesised that a hepcidin-guided screen-and-treat approach to iron supplementation 
would be non-inferior to the WHO-recommended universal daily supplementation and by 
lowering the total exposure to iron would have a better adherence, side effect and safety 
profile. We assessed this in a 12-week randomised-controlled, double-blind, non-inferiority 
trial in Gambian pregnant women with Day 84 haemoglobin as the primary outcome. 
 
PARTICIPANTS AND METHODS  
Full details are in Supplementary Methods and the published trial protocol paper.22 
 
Study design 
The Hepcidin and Anaemia in Pregnancy (HAPn) study was a randomised, double-blind, 
proof-of-concept, non-inferiority trial with pregnant women randomly allocated to: a) daily 
supplementation with UNU/UNICEF/WHO international multiple micronutrient capsules 
(UNIMMAP) containing 60mg iron as ferrous fumarate (Reference, REF); b) weekly 
screening of plasma hepcidin for 12 weeks, each time succeeded by daily supplementation 
for 7 days with UNIMMAP containing 60mg iron (as ferrous fumarate) if plasma hepcidin 
concentration was <2·5µg/L, or no iron if hepcidin was ≥2·5µg/L (S&T60); c) screen-and-
treat supplementation as in b), but with UNIMMAP containing 30mg/day iron (S&T30). 
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Calculation of the hepcidin threshold of <2·5µg/L to define ‘ready-and-safe’ to receive iron 
has been described previously19. The intervention started at Day 0 (the day of screening, 
enrolment and randomisation) and continued for 84 days or until delivery, whichever came 
first. Data collection started 16th June 2014 and ended 3rd March 2016. 
 
Primary and secondary outcomes 
The primary outcome was haemoglobin a Day 84. Secondary outcome measures were: 
proportion of anaemia (Hb < 11g/dl) at Day 84; prevalence of iron deficiency at Day 84; 
prevalence of iron deficiency anaemia (IDA) at Day 84; total iron dosage; adverse events; 
and compliance22. 
 
Ethics, governance, safety monitoring and informed consent  
The trial was approved by the Medical Research Council (MRC) Unit The Gambia Scientific 
Coordinating Committee (SCC), Joint Gambia Government/MRC Ethics Committee (SCC 
1357, amendments L2014.56v2) and London School of Hygiene and Tropical Medicine 
Ethics Committee (7168), overseen by a Data Safety Monitoring Board (DSMB), Trial 
Steering Committee and Trial Monitor, and conducted according to Good Clinical Practice 
(GCP) standards supervised by the MRCG@LSHTM Clinical Trials Office. All participants 
gave written, informed consent. 
 
Study setting  
We conducted the study in 19 rural communities in the Jarra West and Kiang East Districts 
where anaemia is common. Malaria endemicity is low, heterogeneous and seasonal.  
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Recruitment, screening and enrolment  
Nurse midwives and fieldworkers identified and screened pregnant women at first antenatal 
care visits at two health facilities, obtained informed consent and collected demographic 
information. Qualified personnel recorded the medical history, performed a medical 
examination and collected 5-7mL venous blood for field measures of haemoglobin 
(HemoCue Hb301 analyser, Sweden) and a malaria rapid test (SD Bioline MalariaAgPf, 
Standard Diagnostics, Korea) followed by microscopy of positive samples. Blood samples 
were transferred on ice to the laboratory at MRCG@LSHTM Keneba fieldstation for full blood 
count (Medonic M Series) and assessment of plasma hepcidin (see below). At Days 0,14,49 
and 84 freshly washed red blood cells (RBCs) were used for malaria growth assays. 
Remaining plasma was stored at –20°C for iron and bacterial growth assays. Day 14 was 
selected for the ex vivo malaria assays as a time when there would likely be a high level of 
reticulocytosis. Day 49 was then selected as the midpoint between Days 14 and endpoint at 
Day 84. 
 
Women aged 18–45y were eligible for randomisation if gestational age was 14–22wks 
assessed by reported first date of last menstrual period or, in absence of recall, by fundal 
height. Exclusion criteria were: unlikely to remain in the area; severe anaemia (haemoglobin 
concentration <70g/L); serious illness; chronic disease; and self-reported history of previous 
pregnancy complications (repeated miscarriage, or abortions, pre-eclampsia/eclampsia). At 
enrolment, women were provided with long-lasting insecticide-treated bed nets. Any woman 
found to have haemoglobin <70g/L during the trial was treated as per the national protocol.  
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Randomisation  
On the day of screening, eligible women were randomly allocated using computer-generated 
numbers to one of 3 intervention arms based on a stratified, permuted block design (n=9) 
with a 1:1:1 allocation ratio, balanced by haemoglobin (above and below median 
haemoglobin of the respective day) and gestational age (14–18wks or 19–22wks; to account 
for natural differences in haematological and iron status).  
 
Investigational product and blinding to intervention 
The UNICEF/WHO/UNU international multiple micronutrient preparation (UNIMMAP) was 
produced in 3 variants (containing 60mg, 30mg or no iron) by DSM South Africa as identical 
gelatine capsules, packed in tubs under Good Manufacturing Practice (GMP) conditions. All 
formulations contained 400µg folic acid and 13 other micronutrients (see Supplementary 
Table 1). Participants and the research team, with exception of the data manager, were 
blinded to the group allocation and supplementation type throughout the fieldwork. The 
supplements were pre-packed weekly by the field coordinator using computer-generated 
lists accounting for each participant’s preceding hepcidin value. Participants were instructed 
to take 1 capsule a day with water or another drink. 
  
Follow-up 
On Day 2 and weekly thereafter, each woman was seen by a fieldworker who counted 
remaining supplements, measured axillary temperature, recorded self-reported side effects, 
and gave the next week’s supply of tablets. At Days 14,49 and 84, 5-7mL venous blood was 
collected for assessments and processing as described for baseline. At Day 7 and weekly 
thereafter (except when venous blood was collected), field staff collected finger-prick 
capillary blood samples. At each time point, haemoglobin was measured by HemoCue, P 
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falciparum infection by rapid test, and hepcidin concentrations were measured to determine 
their subsequent allocation of iron or no iron in groups S&T60 and S&T30. To maintain 
blinding, participants in the REF group also had weekly finger-prick blood samples collected 
and hepcidin concentrations analysed, even though it did not influence their subsequent 
supplement allocation. 
 
Gambian national guidelines stipulate that pregnant women should receive intermittent 
preventative treatment against malaria with sulfadoxine-pyrimethamine beginning at 16wks 
gestation as first dose and at least 2 other doses with one month interval between them. So 
as not to interfere with the malaria susceptibility assays, we arranged that participants 
received their first dose immediately after blood draws on Day 49.   
 
Participants were monitored until delivery and the outcomes of the pregnancy were 
registered for both mother and child (postnatal check-up within 72h after delivery). 
Where possible, reasons for being lost to follow up were recorded. Adverse events 
were defined as any untoward or unfavourable medical occurrence, including signs 
and symptoms which are temporally associated with the research procedure or trial 
intervention, whether or not considered related to the subject’s participation in the 
research. Serious adverse events were investigated by a physician and defined as 
any adverse event that was life-threatening or resulted in death or required 
hospitalisation or prolongation of hospitalisation; was a persistent or significant 
disability/incapacity; was a congenital anomaly/birth defect; or a reported maternal 
death, miscarriage or stillbirth.  
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Laboratory analyses 
Plasma hepcidin was assayed by ELISA (hepcidin-25 (human) EIA Kit, Bachem; now sold 
by Peninsula Laboratories International, USA) with a detection range 0·049-25·0µg/L. The 
assay was validated as part of a worldwide harmonization exercise23.  Hepcidin was 
quantified as single measurements to allow results within 24h after blood collection and due 
to cost.  
 
Serum ferritin, iron, unbound iron binding capacity, transferrin saturation (TSAT), soluble 
transferrin receptor (sTfR), C-reactive protein (CRP), and α1-acid glycoprotein (AGP) were 
measured by an automated analyser (CobasIntegra400plus, Roche Diagnostic, 
Switzerland).  
 
Ex vivo growth rates of P falciparum parasites in fresh red blood cells and 4 sentinel 
bacterial species in heat-inactivated serum were conducted as proxy safety indices using 
methods described previously.15,24 The bacteria were selected as frequent causes of sepsis 
in low-income settings and as representing a range of iron acquisition mechanisms. Assays 
for one of the bacteria (Staphylococcus epidermidis) proved unreliable with frequent absence 
of any growth so have been excluded from the results. The technical reasons for this were 
discovered in hindsight and there was insufficient sample to rerun them. 
 
Sample size determination 
Haemoglobin concentration data obtained from a prior study in neighbouring villages25 
yielded a standard deviation of 12·8g/L. This value was used to calculate a sample size of 
154 participants for each of the 3 arms using a 1-sided α of 2·5 percent with a conservative-
Bonferroni type correction. Initially, a total sample size of 462 pregnant women was 
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calculated assuming <10% loss to follow-up. This was to provide 80% power to establish 
that, for the primary endpoint haemoglobin, at a non-inferiority margin of 5·0g/L: 1) S&T60 is 
non-inferior to REF; 2) S&T30 is non-inferior to REF; and 3) S&T30 is non-inferior to S&T60. 
After the first 2 cohorts, permission was obtained from the Ethics Committee to increase the 
sample size to 498 as loss to follow up exceeded 10%.  
 
Statistical analysis  
The following definitions were used: anaemia = haemoglobin concentration <110g/L; iron 
deficiency (ID) = plasma ferritin concentration <15µg/L if CRP<5mg/L or ferritin<30µg/L if 
CRP>5mg/L; iron deficiency anaemia (IDA) = Hb<110g/L and ferritin<15µg/L when CRP is 
<5mg/L OR Hb<110g/L and ferritin<30µg/L when CRP is >5mg/L and ferritin index >2·0. 
Adherence was calculated as described in the Supplementary Methods. 
 
Per-protocol analysis was used to assess non-inferiority of the primary end point 
(haemoglobin at D84). All missing values and outliers present after the locking of the 
data were maintained. In the intention-to-treat analysis, missing values were 
replaced by multiple imputation (see Supplementary Methods). Intervention effects 
on continuous variables were measured as the difference in means, with logarithmic 
transformation as appropriate. A modified intent-to-treat analysis was also performed 
(excluding the 3 participants withdrawn before the first dose of supplement) and 
groups were compared using linear regression analysis, with intervention entered as 
a dummy-coded categorical variable. 
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The number of adverse events was too low to allow meaningful analysis by type of 
adverse events. For each woman, we added the counts for various types of adverse 
events. We used negative binomial regression to assess group differences in 
observed counts. Negative binomial regression was used instead of Poisson 
regression to account for over-dispersion (i.e. where the variance exceeds the 
mean). Effect sizes thus obtained are reported as the relative change in observed 
counts. Adherence was assessed as the extent to which the participant’s history of 
supplementation coincided with the prescribed supplementation (see supplementary 
material). 
 
RESULTS 
 
Participant flow  
Between June 2014 and March 2016, we identified 527 pregnant women with gestational 
age 14–22wks who consented to take part in the trial. To ensure that the study was 
conducted across different seasons and to ensure that detailed monitoring could be 
achieved, the study was conducted in 6 cohorts starting June 2014 (n= 52), September 2014 
(n=87), January 2015 (n= 99), April 2015 (n=75), August 2015 (n=96), December 2015 
(n=91). Of those, 29 were excluded for reasons stated in the CONSORT diagram (Figure 1). 
Of the 498 participants who were enrolled and randomly allocated to intervention arms, 78 
(15·7%) were withdrawn or lost to follow up before the scheduled completion of the 
intervention, with no evidence of a marked imbalance in non-completion between groups 
(Figure 1). Three participants were excluded before the first supplement was received, 
resulting in 495 women being included in the modified intention-to-treat analysis.  
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Group characteristics at baseline 
Baseline characteristics were similar between intervention groups (Supplementary Table 
2), and indicated a population with high prevalence of anaemia (>50%) in all three groups.  
One third of all women were iron deficient using ferritin thresholds adjusted for inflammation. 
Poor population iron status was confirmed by the high prevalence of other iron markers with 
abnormal values (hepcidin (54%), mean corpuscular volume (82%), transferrin saturation 
(35%), sTfR (36%)) (Supplementary Table 2). Inflammation measured by CRP and AGP 
was high (32%). Sickle cell disorder was absent. There was only one positive test for 
Plasmodium infection.  
 
Effect of Intervention 
Figure 2 shows the per protocol non-inferiority analysis for the primary endpoint of 
haemoglobin concentration at Day 84 (with confidence intervals listed in Table 1). The 
screen-and-treat approaches did not exceed the preset non-inferiority margin of -5g/L 
(endpoint Hb: S&T60 -2·2g/L, 95%CI: -4·6, 0·1g/L (n=133); S&T30 -2·7g/L, 95%CI: -5·0 -
0·5g/L (n=147) versus REF (n=140)). On the other hand, the upper limit of the confidence 
interval for S&T60 was borderline lower than REF and for S&T30 was clearly lower. The 
effect of S&T30 was not substantively different to S&T60 (-0·5g/L, 95%CI -2·8, 1·8g/l) 
Intention-to-treat analysis was similar (endpoint Hb: S&T60 -1·3g/L, 95%CI: -3·5, 1·0g/L 
(n=164); S&T30 -2·9g/L, 95%CI: -5·1, -0·7g/L (n=165) versus REF (n=165). 
 
Table 1 also shows the intervention effects for secondary outcomes assessed as continuous 
variables. Hepcidin, ferritin and the sTfR/log-ferritin ‘ferritin index’ (measures of iron 
deficiency) were all significantly lower than REF in both S&T groups. The other iron markers 
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(serum iron, transferrin, sTfR, and unbound iron binding capacity) confirmed these results 
(see Supplementary Results and Supplementary Table 3). 
 
The prevalence of anaemia and iron deficiency showed a similar picture though the 
contrasts appear more striking (Table 2). In the REF group the anaemia prevalence dropped 
from 58·2% to 45·3%; and rose in the other two groups (S&T60, 52·2% to 57·3%; S&T30, 
52·8% to 59·3%) such that the S&T arms were clearly inferior to REF. Similarly the 
prevalence of ‘ready-and-safe’ to receive iron (defined as hepcidin <2·5µg/L) declined 
substantially (from 56·0% to 21·4%) in the REF arm and at endpoint was lower than both 
S&T groups, indicating better iron status (S&T60: 41·7%; S&T30: 52·4%; REF: 21·4%)(see 
Supplementary Figure 3). The prevalence of iron deficiency (defined as ferritin <15µg/L 
when CRP<5 or <30µg/L when CRP>5) declined more in the REF group (38·6 to 17·1%) 
than in the S&T60 (39·6 to 29·0%) and S&T30 group where it increased slightly (37·0 to 
39·7%). Iron deficiency prevalence defined using the sTfR threshold of >4·4mg/L showed a 
very similar pattern where the prevalence of iron deficiency anaemia were also higher in the 
S&T groups at the end of intervention. 
 
Adherence and supplement use 
Adherence exceeded 86% in all groups and was similar between groups (Table 2). 
Participants in S&T60 and S&T30 groups received 46% and 52% of the number of 
supplemental iron doses received by their peers in REF, respectively. 
 
Adverse events 
The risk of self-reported illnesses and side effects (black stool, constipation, dizziness, 
fatigue, nausea and stomach ache) was similar in the S&T60 group (13·7%) to that in the 
   
 
Page 76 of 185 
 
 
REF group (11·1%; difference 2·5, 95%CI 0·3%, 4·8%); in the S&T30 group it was lower than 
in REF (7·8%; difference -3·5%, 95%CI -5·4%, -1·6%) (Table 2).  
 
The frequency of adverse events or serious adverse events was similar between the groups 
(Table 2). 
 
Safety assays 
Figure 3A shows that the growth of malaria parasites in fresh RBCs was suppressed at 
baseline (compared to the non-anaemic controls used in the assay), was greatly stimulated 
at Day 14 and gradually declined to Day 84, with no differences between the intervention 
groups at any timepoint.  
Figure 3B illustrates the ex vivo growth of Escherichia coli, Salmonella enterica and 
Staphylococcus aureus in heat inactivated sera from the participants. These sentinel 
bacteria were selected on account of their differing iron acquisition mechanisms. For each 
organism replication rates were significantly faster in serum drawn 14, 49 and 84 days after 
the commencement of iron supplementation. On Days 14 and 49 there were no differences 
between treatment arms. On Day 84 sera from women in the REF arm supported faster 
bacterial growth than in S&T30 for E coli and S aureus, and for E coli growth in REF was 
also faster than in S&T60. This effect was due to the acute effect of iron administered to 
those women in S&T60 and S&T30 whose hepcidin measured 7 days previously was below 
the 2·5µg/L threshold. This is verified in Supplementary Figure 4 which shows that there is 
no difference in bacterial growth across intervention groups among women who received 
iron 3h prior to the blood draw, and significantly lower growth in those in S&T60 and S&T30 
who did not have iron. 
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Discussion 
 
The World Health Organisation recommends universal daily oral iron and folic acid 
supplementation for pregnant women to prevent maternal anaemia, puerperal sepsis, low 
birth weight, and preterm birth.2 Implementation of this policy in low-income countries is 
highly variable and adherence is notoriously poor; the latter in large part due to the common 
side-effects of gastric discomfort, black stools, nausea and dizziness.2 In recognition of 
these problems WHO also endorses intermittent supplementation10, which might help 
overcome the fact that iron administration raises hepcidin and reduces the absorption of iron 
on the following day 26,27. However, efficacy of weekly supplementation in reducing anaemia 
is generally low.11 There is clear evidence that iron supplementation has the greatest benefit 
in iron deficient women,4 and moderately strong evidence that administration of iron might be 
harmful in women who are iron replete;4 all of which suggests that a screen-and-treat 
approach would be beneficial.  
 
In this study, we reasoned that hepcidin would be the ideal marker for defining ‘ready-and-
safe’ to receive iron because it is a highly specific measure of iron status 18,19 and 
additionally records if women, due to on-going infection or inflammation, might be at risk 
from iron 15,16 and would anyway not absorb it.20 We simulated a point-of-care test using 
weekly finger-prick blood sampling and overnight ELISA analysis.  
 
The hepcidin-guided approach approximately halved the iron exposure in the two screen-
and-treat groups; S&T60 and S&T30 received iron in 46·2% and 52·6% of weeks in the 
intervention period, respectively. Since the amount of iron was halved in S&T30 the overall 
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iron intake was only 26.3% as much as in REF.  The primary outcome (haemoglobin at Day 
84) was lower in both S&T groups. In S&T60 the lower limits of the 95% CI were within our 
pre-set non-inferiority margin of -5g/L (-2·2g/L, 95%CI: -4·6, 0·1g/L, n=133). In the S&T30 
group the lower limit of the 95% CI touched on the non-inferiority margin (-2·7g/L, 95%CI: -
5·0, -0·5g/L, n=147). All of the secondary outcomes for iron status showed evidence of 
inferiority. Anaemia prevalence declined in the universal supplementation REF arm and 
increased in both S&T arms. Likewise, the prevalence of ID determined by ferritin, sTfR, 
ferritin index or hepcidin thresholds was higher in both S&T groups than the REF group and 
similarly for IDA. 
 
As in many trials,3,4 even the REF arm had low apparent efficacy, with only a 3·3g/L 
improvement in haemoglobin and only a 13% reduction in anaemia, despite being 
implemented under the ideal conditions of an efficacy trial. However, true efficacy in 
ameliorating the haemodilution of pregnancy cannot be judged in the absence of a placebo 
arm.  
 
Iron is a problematic nutrient with both beneficial and potentially harmful effects. Some of 
these effects are potentially serious especially in low-income settings where infections are 
common.28 Detection of differences in event rates for serious infections would require a very 
large trial and, in the case of malaria, would be unethical since intermittent preventive 
therapy for pregnant women is advised, and in The Gambia mandated. We also issued 
insecticide-treated bed nets to all participants at enrolment. In light of these constraints we 
used proxy assays of likely infection potential for malaria and for three sentinel bacteria that 
use a range of iron acquisition mechanisms. By conducting these ex vivo assays at baseline, 
Days 14 and 49 we were able to capture the short- and medium-term effects of chronic iron 
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administration. On Day 84 blood was drawn 3h after the last oral iron (or placebo) dose and 
hence results at Day 84 capture both the chronic and acute post-absorptive effects of iron. 
The malaria parasite assays have previously provided a robust mechanism to explain how 
IDA protects against P falciparum infection (parasite invasion and growth rates are poor in 
older microcytic RBCs) and why supplementation abrogates this effect (parasite invasion 
and growth rates are high in reticulocytes and large young RBCs).15,29,30 These effects are 
clearly replicated in Figure 3A and concur with the associated changes in CD71 (a 
reticulocyte marker). There was no difference between treatment arms at any timepoint. This 
can be explained by the fact that the most iron deficient subjects in all groups received iron 
early in the trial and this elicited a broadly similar reticulocyte surge despite the poorer 
overall performance of the two S&T arms. Reticulocytosis is also a natural response to the 
expansion of blood volume in mid-pregnancy and may have contributed to the increased 
risk.31 Note that the absence of an acute effect of iron administration at Day 84 is entirely 
consistent with the fact that the assay uses washed RBCs and their susceptibility is 
governed by cell morphology rather than iron content.24 
 
Growth rates of all three bacteria rose markedly in all treatment groups after commencement 
of iron supplementation. In the absence of a placebo group we cannot conclude that this is 
an effect of the iron (or other micronutrients), but it seems highly likely. Pregnancy-related 
changes in humoral immunity are an unlikely explanation since the plasma was heat-
inactivated prior to inoculation. Furthermore, the growth-stimulatory effect of iron is clearly 
illustrated by the response to the acute iron and micronutrient administration 3h before the 
blood draw on Day 84 shown in Supplementary Figure 4. This corroborates our previous 
results in adult men where growth rates were promoted by prior iron (without additional 
micronutrients) and were highly correlated with serum iron and transferrin saturation.24 
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These ex vivo assays may not equate to the situation in vivo but are highly suggestive that 
blood-stream bacteria would grow faster at higher levels of iron and transferrin saturation, 
and would therefore have a greater chance of overcoming immune defences. 
 
The real or perceived side effects of taking oral iron supplements are less serious than the 
threat of a major infection but are important insofar as they lead to poor adherence to iron 
supplementation. The poorer performance of the S&T arms in resolving ID and IDA might 
have been acceptable if there was evidence that they were safer or had fewer side effects, 
as we initially hypothesised. In fact there was a higher prevalence of self-reported illnesses 
and side effects in the S&T60 group; possibly because women in the REF arm adapted to 
the iron better than when administration was intermittent (with on and off weeks). As might 
be expected the prevalence of illnesses and side effects was lower in the S&T30 group. 
Note that the unusually high adherence in this study may reflect the influence of sensitization 
and fieldworker encouragement, and the fact that subjects were aware that adherence was 
being monitored. 
 
There are several possibilities why the screen-and-treat approach failed. First, it is possible 
that weekly screening fails to capture the dynamics of inter-current infections and 
inflammation, and that more frequent screening is needed. Even if this were the case and a 
point-of-care test were available, it would be entirely impractical to screen more frequently. A 
second possibility is that our hepcidin threshold, determined to diagnose iron deficiency,19 
did not adequately differentiate iron absorbers from iron blockers (because the derivation did 
not include information on iron absorption). A higher threshold might have yielded more 
frequent dosing and a higher efficacy, but would have been less effective at total number of 
women given iron, and should not have been necessary because we already prioritised 
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sensitivity over specificity in selecting the threshold (see Supplementary Methods). A lower 
threshold would have reduced efficacy yet further. Our surmise is that the large bolus doses 
of highly-absorbable ferrous fumarate override the physiological mechanism of hepcidin-
induced iron blockade evolved to regulate duodenal iron absorption from foods; and hence 
iron continued to be absorbed in the REF group even in the face of raised hepcidin. 
 
Our study had numerous strengths and some weaknesses. Hepcidin is theoretically the ideal 
index of ‘ready-and-safe’ to receive iron and it very effectively reduced the amount of iron 
administered in an area with high anaemia prevalence. The study had adequate statistical 
precision for the main outcomes, conducted to GCP standards, had high adherence and 
relatively few drop outs. A limitation is that sample size was insufficient to capture potentially 
rare adverse events and the trial was conducted in an area with low malaria transmission, 
and high use of insecticide-treated bed nets and intermittent preventive treatment for 
pregnant women, and hence could not assess to what extent the S&T approach reduced the 
risk of malaria. Our proxy safety outcomes for malarial and bacterial infections provide 
intuitively solid outcomes, but may not reflect in vivo susceptibility. Provision of the iron with 
multiple other micronutrients can be viewed as both a strength and a weakness; a strength 
because other nutrient deficiencies that might limit the acquisition and/or utilisation of iron 
should be eradicated or a weakness because of possible nutrient-nutrient interactions (eg 
that the zinc in UNIMMAP might compete with iron for absorption). Note also that the 
UNIMMAP capsules are not enteric coated; this will not affect aggregate iron availability but 
mat cause loss of other micronutrients. Because all subjects received the same UNIMMAP 
excepting for differences in iron content the latter concern would not affect comparison 
between the intervention arms. 
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Prior evidence demonstrates that intermittent iron supplementation in pregnancy is 
somewhat less efficacious than daily supplementation 4,11 and we conclude from this study 
that a hepcidin-guided screen-and-treat strategy does not overcome this limitation. These 
results are likely to be generalizable at least to other populations in LMICs with high levels of 
anemia and iron deficiency and in a low malaria setting. Future alternatives to universal oral 
iron supplementation in pregnancy may include use of parenteral iron formulations such as 
ferric carboxymaltose which can deliver up to 1000mg elemental iron over a 15-minute 
infusion; this will require evidence of cost effectiveness and safety in low income settings 
together with development of infrastructure to overcome barriers to implementation.  
We therefore support continued application of the current WHO guidelines, but urge 
development of novel iron formulations with a much better side-effect profile in order to 
encourage better adherence. The findings from our RBC malaria susceptibility assays 
underscore the importance of the WHO guideline that iron administration in malarious areas 
should ideally be implemented in conjunction with adequate measures to prevent, diagnose 
and treat malaria.32 
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Table 1: Primary and secondary trial outcomes; continuous variables (per-protocol). 
Outcome Intervention Group n (%) of 
randomised 
Estimate 
 
SE¶  Effect [95% CI] 
Primary outcome 
     
Haemoglobin, g/L REF 139 (83·7) 110·1 0·8 
 
 
S&T60 131 (79·9) 107·9 0·8 -2·2 [-4·6, 0·1] 
 
S&T30 145 (87·9) 107·4 0·8 -2·7 [-5·0, -0·5] 
Secondary outcomes      
Hepcidin, µg/L *† REF 140 (84·3) 6·3 3·4  
 S&T60 132 (80·5) 3·3 4·2 0·52 [0·37, 0·75]  
 S&T30 147 (89·1) 2·3 4·7 0·37 [0·26, 0·52]  
Ferritin, µg/L † REF 139 (83·7) 34·6 1·9  
 S&T60 130 (79·3) 23·1 1·8 0·67 [0·58, 0·77] 
 S&T30 145 (87·9) 21·4 1·7 0·62 [0·54, 0·71] 
Ferritin (inflammation adjusted) REF 139 (83·7) 31·6 0·1  
 S&T60 130 (79·3) 21·2 0·1 0·67 [0·58, 0·77] 
 S&T30 145 (87·9) 19·3 0·1 0·61 [0·53, 0·70] 
Ferritin index† REF 139 (83·73) 2·2 1·5  
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 S&T60 129 (78·66) 2·9 1·5 1·35 [1·23, 1·49] 
 S&T30 145 (87·88) 3·1 1·5 1·43 [1·31, 1·58] 
 
 
* Estimates obtained using Tobit regression on the natural-log transformed hepcidin concentration was left-censored at 0·049 µg/L 
(limit of detection) and right-censored at 25 µg/L. 
Values indicate mean (SE) or † geometric mean (GSD as geometric standard deviation). Exponentiation of log-transformed 
variables † yielded effect estimates that are expressed as ratios of geometric means versus REF. 
¶ SE = standard error obtained by the Delta method. 
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Table 2: Secondary trial outcomes; categorical variables (per-protocol) 
 
Outcome Intervention Group Prevalence, 
% 
n/N Effect [95% CI]  
 
    
Anaemia (haemoglobin <110g/L) REF 45·3 63/139  
 
S&T60 57·3 75/131 11·9 [0·1, 23·8] 
 
S&T30 59·3 86/145 14·0 [2·5, 25·5] 
Ready-and-safe to receive iron (hepcidin <2·5µg/L) REF 21·4 30/140  
 
S&T60 41·7 55/132 20·24 [9·42, 31·05] 
 
S&T30 52·4 77/147 30·95 [20·40, 41·51] 
Ferritin index (sTfR/logferritin ratio >2·0) REF 58·6 82/140  
 S&T60 87·2 116/133 28·6 [18·7, 38·6] 
 S&T30 89·1 131/147 30·5 [21·0, 40·1] 
Iron deficiency anaemia (see legend1, %) REF 17·1 24/140   
 S&T60 29·0 38/131 11·9 [1·9, 21·8] 
 S&T30 39·7 58/146  22·6 [12·5, 32·7] 
Iron dosage (% of weeks in which iron was received) REF 100.0 1974/1974 
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S&T60 46·2 1025/1905 -53·8 [-56·0, -51·6] 
 
S&T30 52·6 952/2009 -47·4 [-49·6, -45·2] 
Adherence/compliance (%) REF 86·1 275/1974  
 S&T60 86·3 260/1905 0·3 [0·3, 0·3] 
 S&T30 87·8 246/2009 1·7 [1·7, 1·7] 
Reported side effects (aggregate score2)3 REF 111 220/1974  
 S&T60 135 261/1906 1·2 [0·8, 1·8] 
 S&T30 78 154/2009 0·7 [0·5, 1·0] 
Adverse events 3 REF 89 167/1902  
 S&T60 82 149/1861 -7·4 [-26·0, 11·1] 
 S&T30 89 175/1945 1·6 [-17·2, 20·3] 
Serious adverse events (DSMB notified)4 REF 29 9/1904  
 S&T60 47 14/1861 18·7 [-12·3, 49·8] 
 S&T30 18 6/1945 -10·2 [-34·0, 13·6] 
 
1 IDA defined as Hb<110g/L and ferritin <15ug/L when CRP is <5mg/L OR Hb <110g/L and ferritin <30ug/L when CRP is >5mg/L and ferritin 
index >2·0. 
2 Individual complaints and events are listed in Supplementary Table 5. 
3Prevalence = Observed number of events per 1000 person-weeks; n/N = Cases/Person-weeks  
4 Prevalence = Observed number of events per 10,000 person-weeks; n/N = Cases/Person-weeks 
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The estimates from 3 & 4 above were based on a negative binomial model, accounting for differences in exposure. The effect and its 
accompanying 95% CI are the respective exponentiated relative changes in observed counts and their CIs. 
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Figure Legends 
 
Figure 1: CONSORT diagram for participant flow 
 
Figure 2: Non-inferiority tests for the primary outcome at endline  
 
Per protocol analysis of change in haemoglobin from baseline to Day 84. Values are means 
± 95% CI. Dotted line shows the pre-set non-inferiority margin of -5g/L. 
 
Figure 3: Ex vivo assays of malaria growth in erythrocytes and sentinel bacteria 
growth in serum 
 
3A: Malarial growth assays in fresh red blood cells. Left panel shows growth rates of P 
falciparum strain FCR3-FMG in fresh red blood cells (RBCs) relative to the growth in RBCs 
from non-anaemic controls. Right panel shows reticulocyte counts assessed by FACS 
counting of CD71+ cells relative to non-anaemic controls. Parasite growth and reticulocyte 
counts were significantly higher at Days 14 and 49 compared to baseline (P<0·001) with no 
differences between treatment groups. Blue = REF, red = S&T60, green = S&T30. 
 
3B: Sentinel bacterial growth assays in serum. Upper section shows individual patient 
data with means ±SE. Growth rates were assessed as change in optical density at 6h post 
inoculation for E coli, 7h for S enterica and 8h for S aureus. Blue = REF; red = S&T60; green 
= S&T30. *** P<0·0001; ** P<0·001. Differences between time points were assessed by 
repeat measures ANOVA and Scheffé’s post-hoc tests. Days 14, 49 and 84 showed faster 
growth rates than at baseline for all species (P<0·0001 for all times). The lower plots show 
the percentage of patient sera displaying ex vivo growth rates greater than the 95% centile 
calculated at baseline across all groups. All organisms showed significant increases 
following iron supplementation (P<0·01). Differences between the intervention groups were 
not significant by Chi-squared tests. Blue = REF, red = S&T60, green = S&T30. 
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Fig 1 
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Fig 2 
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Fig 3A 
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Fig 3B 
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SUPPLEMENTARY METHODS 
The full trial protocol has been previously published 1. 
 
Schematic representation of trial design 
Supplementary Figure 1 
 
 
 
Derivation of the hepcidin threshold to define ‘ready-and-safe’ to receive iron 
The hepcidin cut-off value of <2·5µg/L as a threshold to receive iron was based on the analysis 
of plasma from 395 pregnant women participating in the ENID study 2 with samples available 
for 3 time points (14wks, 20wks and 30wks gestation). Based on a reference standard of 
ferritin concentration <15µg/L and body iron content <0mg/kg, we constructed a receiver 
operating characteristic (ROC)-curve and calculated the area under the curve (AUCROC). The 
general suppression of hepcidin in pregnancy indicated that many women were ready to utilise 
iron. To make sure these women were not missed, we optimised for sensitivity over specificity, 
across the duration of pregnancy. At a hepcidin concentration of <2·5µg/L with a high Youden 
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index, we had corresponding sensitivity and specificity values of 93·1% and 66·3% at 14wks, 
86·1% and 52·2% at 20wks, and 86·2% and 84·9% at 30wks. The full method is described 
elsewhere 3.  
· 
Additional information on informed consent procedures 
The Regional Health Team, local health staff and individual communities were informed and 
approved the study. We trained all field workers who took part in the recruitment of participants 
on translating the informed consent documents. We also translated the information sheet to 
all the non-literate participants in a language they understand in the presence of an 
independent witness. The literate participants read the information sheet in their own time. 
Participants were encouraged to ask questions and seek clarification from the field workers 
and the PI. We recorded by a signature or thumbprint the informed consent of all the 
participants who agreed to take part in the study. 
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Investigational product 
The composition of the three formulations of UNIMMAP (containing 0, 30 and 60mg iron) is 
listed below.  
 
Supplementary Table 1 
Composition of the experimental supplement based upon the UNIMMAP formulation 
 
Micronutrients Dose/day Ingredients 
Vitamin A (µg RE) 800  Dry vitamin A acetate 325  
Thiamine (mg) 1·4  Thiamine mononitrate 
Riboflavin (mg) 1·4  Riboflavin 
Niacin (mg) 18  Niacinamide 
Vitamin B6 (mg) 1·9 Pyridoxine hydrochloride 
Folic acid (µg) 400  Folic acid food grade 
Vitamin B12 (µg) 2·6 Vitamin B12 0·1%  
Vitamin C (mg) 70  Ascorbic acid 
Vitamin D (IU) 200 Dry vitamin D3  
Vitamin E (mg) 10 Dry vitamin E 50%  
Zinc (mg) 15  Zinc oxide 
Iron (mg) 60 or 30 or 0 (placebo) Ferrous fumarate  
Iodine (µg) 150  Potassium iodide 10% on Potato 
Maltodextrin 
Selenium (µg) 65  Sodium selenite anhydrous 
Copper (mg) 2  Copper gluconate 
 
  
 
Additional details on blinding to intervention 
Participants and the research team, with exception of the data manager, were blinded to the 
group allocation and supplementation type throughout the fieldwork. The supplements were 
pre-packed on a weekly basis by the field coordinator in Keneba using lists automatically 
computer generated by the data office taking into account the hepcidin results of the 
participants. The list indicated a participant’s identity number, a letter and number (code W1 
to W6) of the supplement type to be received by the participant in the subsequent 7 days, 
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but the field coordinator did not know which code was allocated to which supplement or who 
belonged to which group.  
 
Additional details on laboratory analyses 
We measured hepcidin concentration in plasma from finger prick blood or from venous blood 
by competitive enzyme-linked immunosorbent assay (ELISA) (hepcidin-25 (human) EIA Kit, 
Bachem; now sold by Peninsula Laboratories International, San Carlos, USA) using 
a microplate photometer (Multiskan FC, Thermofisher Scientific, Waltham, MA, USA) with a 
detection range 0·049-25·0µg/L. Concentrations were interpolated from a 4-parameter curve 
fitted from a 2-fold, 10-point serial dilution made from a manufacturer-provided standard 
peptide. We quantified hepcidin as single measurements to allow results within 24 hours 
after blood collection and due to cost. 
 
We prepared a haemogram from whole blood collected in EDTA tubes (Medonic M Series, 
Boule Diagnostics, Spånga, Sweden), and measured plasma concentrations of ferritin, iron, 
transferrin, soluble transferrin receptor (sTfR), C-reactive protein (CRP), and α1-acid 
glycoprotein (AGP) using an automated analyser (Cobas Integra 400 plus, Roche 
Diagnostic, Rotkreuz, Switzerland). TSAT and UIBC were calculated. 
 
We determined sickle cell status by performing haemoglobin electrophoresis in a Hu15 
Standard Horizontal Gel Unit (Scie-Plas Ltd, Cambridge, UK) with a Shandon Vokam 400 
power pack (Astmoor Rancorn, Cheshire, UK) in blood samples collected at baseline.  
Bacterial growth assays 
Staphylococcus aureus (strain NCTC8325), Staphylococcus epidermidis (FDA strain 
PCI1200, ATCC12228), Salmonella enterica serovar Typhimurium (strain LT2, ATCC19585) 
and Escherichia coli (strain Crooks, ATCC8739) were grown overnight for 18 hours at 37 °C 
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in 5mL iron-free minimal growth media, Iscove’s Modified Dulbecco’s Medium (IMDM, 
Invitrogen). This was conducted in air with continuous shaking (250 rpm). All growth assays 
were run in triplicate in IMDM containing 50% heat-inactivated human serum. Bacterial 
growth was monitored by measuring the optical density at 620 nm (OD620) hourly for 
12 hours (Staphylococcus aureus, Salmonella enterica serovar Typhimurium, 
and Escherichia coli) and then at 20, 28, 36 hours (Staphylococcus epidermidis) using a 
Multiscan FC ELISA plate reader (Thermo Scientific). 
Plasmodium growth assays 
In vitro growth of the FCR3-FMG laboratory strain of P falciparum was assessed in fresh, 
washed RBCs as in4 for 96h (performed in triplicate for RBCs from each study participant). 
RBCs from healthy, non-pregnant, adult iron replete donors of normal haemoglobin 
genotype and G6PD status not undergoing iron supplementation served as controls. Growth 
rates represent final 96h parasitaemia divided by initial 0h parasitaemia, analysed by flow 
cytometry4. 
1.5.1 Quantification of CD71-positive reticulocytes 
CD71-positive reticulocytes in fresh RBCs were counted using PE-conjugated anti-human 
CD71 antibody (Clone M-A712, BD) and isotype control (Clone G155–178, BD), and 
analysed by flow cytometry for CD71-positive reticulocyte percentage relative to non-
anaemic control as in5. 
 
Additional details on statistical analysis  
Because plasma ferritin concentrations can be increased by inflammation independent of 
iron status, we adjusted for inflammation (concentrations of C-reactive protein and α1-acid 
glycoprotein) measured in the same plasma samples, using approaches based on a Higher 
ferritin cutoff, and Excluding individuals. The higher ferritin cutoff means changing the cutoff 
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to 30µg/L among those with inflammation, whilst the excluding individuals involves stratifying 
women into groups with and without inflammation and use ferritin values only among those 
without inflammation. 
 
In the intention-to-treat analysis, missing values were replaced by multiple imputation using 
a Multiple Imputation Chained Equation with a burn-in of 100 and 100 imputations, including 
the following variables: gestational age, HemoCue haemoglobin concentration, hepcidin, red 
blood cells, mean corpuscular volume, red cell distribution width, haematocrit, mean platelet 
volume, white blood cells, Medonic haemoglobin, mean corpuscular haemoglobin 
concentration, lymphocytes, granulocytes, parity, gravida and age at start of study.  
 
For individual women, we estimated adherence as the number of days that supplements 
were taken according to the capsule count (minus 2 days to account for the first two days 
after randomisation when supplementation was put on hold depending on the results of the 
first hepcidin concentration assessment) divided by the number of days between enrolment 
and leaving the study for reasons that were unrelated (or likely to be unrelated) to 
supplementation use (i.e., attaining the end of the 85-day intervention period, delivery, or 
emigration, whichever came first). Thus, as the denominator, we used the 85-day 
intervention period for women who refused, who were withdrawn for medical or unknown 
reasons, or who were withdrawn because of poor compliance. For groups, we calculated 
adherence by dividing the pooled number of days that supplements were taken as assessed 
by capsule count for all women by the pooled number of days until the end of the 
intervention period for all women. Details of calculation methods are shown in 
Supplementary Figure 2. 
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Supplementary Figure 2 
 
Methods used to describe supplement use in groups allocated to screen-and-treat 
supplementation with iron 
 
 
 
 
LEGEND: Panel A: schematic representation of the scheduled intervention period and visits 
made to hand out supplements and to assess adherence. Panel B: follow-up time and 
exposure to supplementation for three individual study participants in the screen-and-treat 
groups (hypothetical data). Each participant was provided with 7 supplements per week for 
the duration of the study, but whether these supplements contained iron or placebo depended 
on hepcidin concentrations in plasma or serum samples collected two days earlier. Weekly 
measurement of hepcidin concentrations started at Day 0; weekly provision of supplements 
started at Day 2. Results of the plasma/serum tests are shown by +/‒ -signs, indicating 
hepcidin concentrations <2·5μg/L or ≥2·5μg/L, respectively. Values in red font indicate the 
number of iron-containing supplements provided each week; values of 0 indicate that 
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participants were provided with placebo. Values in blue font indicate the number of 
supplements consumed in a single week (calculated as the number prescribed and handed 
out minus the number returned unconsumed), regardless of whether they contained iron or 
placebo. Values in bold font indicate the number of days that each participant took part in the 
study. Circles indicating the end of follow-up show whether the participant left the study for 
reasons considered unrelated to intervention (i.e., completed the 84-day intervention period, 
delivered, or migrated; closed circles), or for reasons that could be related to the use of 
supplementation (i.e. refusal, withdrawn for medical reasons, because of poor adherence, or 
for unknown reasons; open circles). In the latter case, the period between leaving the study 
and the scheduled end of intervention (dashed line) contributed to the follow-up time that was 
used as the denominator of the formula to calculate adherence. For example, participant 1 
completed the intervention period of 84 days. In the first week of supplementation, which 
started at Day 2, she was provided with supplements containing placebo (hence, 0 iron-
containing supplements), which she all consumed. Participant 3 refused further cooperation 
at Day 25; to calculate adherence, however, a follow-up period of 84 days was maintained. 
Panel C: Calculation of results (data from panel B). 
 
 
 
All missing values and outliers present after the locking of the data were maintained and 
analysis performed with them for per protocol analysis. Since the data is longitudinal and at 
baseline most of the observations were non-missing, hence it would be ideal to use these 
values for the predictions of subsequent observations. Firstly, we set the data to identify the 
missing values, the imputation number (which would be zero at this point) and the multiple 
imputation identity. We start by registering the variables that would be required to impute the 
missing values. These variables included gestational age, HemoCue haemoglobin 
concentration, hepcidin, red blood cells, mean corpuscular volume, red cell distribution width, 
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haematocrit, mean platelet volume, white blood cells, Medonic haemoglobin, mean 
corpuscular haemoglobin concentration, lymphocytes, granulocytes, parity, gravida and age 
at start of study. With these variables, we reshaped the data from long to wide, which simplified 
the data such that each individual now has only one row in the dataset. It also means that it is 
easy to use complete outcomes of some of the variables at some of the timepoints to predict 
the values of subsequent outcomes. We used a Multiple Imputation Chained Equation for the 
imputation with a burn-in of 100 and 100 imputations. This would also ensure that the Monte 
Carlo (MC) error is small enough to be unimportant6. The MC error was small enough to 
consider the number of imputations acceptable. The burn-in was adequate to show a 
convergence to a stationary state. 
In the intention-to-treat analysis, missing values were replaced by multiple imputation. 
Intervention effects on continuous variables were measured as the difference in means, with 
logarithmic transformation as appropriate. We based the analysis of the primary end point 
(haemoglobin at Day 84) on the evaluation for non-inferiority with a per-protocol analysis. We 
also as per acceptable practice performed a modified intent-to-treat analysis (i.e., excluding 
participants who were lost to follow-up for being withdrawn before the first dose of supplement 
was received) on the randomised population and compared the groups using linear regression 
analysis, with intervention entered as a dummy-coded categorical variable and using the 
control arm (universal daily supplementation) as the reference group. To indicate non-
inferiority, we used the lower limit of the 95% confidence interval for the difference in mean 
haemoglobin concentration between either of the screen-and-treat arms and the daily 
reference arm which should be above -5·0g/L (non-inferiority margin). 
  
   
 
Page 112 of 185 
 
SUPPLEMENTARY RESULTS 
 
Baseline characteristics of the subjects 
 
See Supplementary Table 2. Groups were similar in baseline characteristics. 
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SUPPLEMENTARY TABLE 2: Baseline characteristics by intervention group 
 
Characteristics REFERENCE S&T60 S&T30 
  n Mean(SD) n Mean(SD) n Mean (SD) 
Age, years 166 27·1 (6·0) 164 27·1 (5·7) 165 27·1 (5·8) 
Number of pregnancies* 166 3·0 [2·0, 5·0] 164 3·0 [2·0, 5·0] 165 4·0 [2·0, 5·0] 
Number of previous live births* 166 2·0 [1·0, 4·0] 164 2·0 [1·0, 4·0] 165 3·0 [1·0, 4·0] 
Gestation age, weeks 166 18·4 (2·5) 164 18·6 (2·6) 165 18·5 (2·7) 
Height, cm 166 163·1 (6·5) 164 161·7 (6·1) 165 162·4 (6·4) 
Weight, kg 166 59·5 (11·4) 164 59·9 (11·2) 165 59·1 (11·3) 
Body mass index, kg/m2 166 22·3 (3·8) 164 22·8 (3·7) 165 22·4 (4·0) 
Sickle cell genotype (AS) ‡ 33/162 20·4 24/162 14·8 29/162 17·9 
Haemoglobin concentration, g/L 
      
By Medonic analyser 166 106·8 (13·7) 164 108·5 (14·2) 165 107·6 (14·5) 
By HemoCue field photometer 166 112·0 (12·4) 164 113·9 (12·9) 165 113·1 (12·8) 
Anaemia (haemoglobin <110g/L) ‡       
By Medonic analyser 96/165 58·2 85/163 52·2 87/165 52·8 
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By HemoCue field photometer  66/166 39·8 57/164 34·8 61/165 37·0 
Haematocrit, % 166 29·3 (3·9) 163 29·8 (4·1) 164 29·4 (3·9) 
Mean corpuscular volume (MCV), fL 166 79·6 (7·2) 163 79·1 (6·4) 164 78·8 (7·2) 
MCV <85 fL‡ 129/166 77·71 136/163 83·44 140/164 85·37 
Mean corpuscular haemoglobin (MCH), pg 166 29·1 (3·1) 163 29·0 (2·7) 164 28·9 (3·1) 
MCH <27 pg‡ 31/166 18·7 32/163 19·6 31/164 18·9 
Mean corpuscular haemoglobin concentration, 
(MCHC) g/dL 
166 365·1 (11·2) 163 364·9 (10·8) 164 366·2 (10·7) 
Erythrocyte distribution width, %* 166 13·3 [12·7, 14·4] 163 13·2 [12·6, 14·5] 164 13·2 [12·6, 14·8] 
Leukocyte count, ×109/L 166 7·5 (2·0) 163 7·5 (2·3) 164 7·2 (1·9) 
Lymphocytes, ×109/L† 166 1·9 (0·3) 163 1·9 (0·3) 164 1·8 (0·3) 
Lymphocytes, % 166 27·7 (7·0) 163 27·8 (7·5) 164 27·1 (6·2) 
Granulocytes, ×109/L† 166 4·7 (0·4) 163 4·7 (0·4) 164 4·6 (0·3) 
Granulocytes, % 166 65·6 (7·8) 163 65·4 (8·3) 164 66·2 (6·9) 
Plasma marker concentrations  
      
Hepcidin, µg/L* 166 1·6 [0·4, 7·9] 164 2·5 [0·5, 8·4] 165 2·0 [0·5, 8·1] 
Hepcidin <2·5 µg/L‡ 93/166 56·0 83/164 50·6 92/165 55·8 
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Ferritin, µg/L* 161 21·2 [12·2, 40·3] 156 23·5 [11·5, 42·6] 152 22·4 [12·9, 42·6] 
Iron deficiency (ferritin <15µg/L CRP <5 mg/L) 
OR (ferritin <30µg/L CRP >5 mg/L) ‡ 
64/166 38·6 65/164 39·6 61/165 37·0 
Iron deficiency anaemia (Hb < 110 g/L ferritin < 
15µg/L CRP <5mg/L) OR (Hb <110g/L ferritin < 
30µg/L CRP >5mg/L & ferritin index > 2) ‡ 
42/165 25·5 46/162 28·4 36/163 22·1 
Transferrin, g/L 162 3·3 (0·7) 160 3·3 (0·6) 160 3·3 (0·6) 
Unsaturated iron binding capacity 
(UIBC), µmol/L 
164 55·0 (18·3) 160 55·5 (15·7) 163 56·2 (16·5) 
Iron, µmol/L 164 15·7 (8·6) 161 14·4 (7·0) 162 14·7 (7·0) 
Iron <8·95 µmol/L‡ 30/166 18·1 40/164 24·4 35/165 21·2 
Transferrin saturation (TSAT) <16%‡ 53/164 32·3 56/160 35·0 57/162 35·2 
Soluble transferrin receptor, mg/L* 164 3·87 [2·85, 4·93] 160 3·99 [3·09, 5·10] 162 3·74 [2·93, 5·01] 
Iron-deficient erythropoiesis (sTfR 
concentration > 4·4 mg/L) ‡ 
58/164 35·4 63/160 39·4 52/162 32·1 
sTTfR log10Ferritin ratio (ferritin index) 154 2·78 (0·60) 149 2·91 (0·65) 149 2·83 (0·57) 
Ferritin index >2‡ 121/166 72·9 113/164 68·9 120/165 72·7 
C-reactive protein (CRP), mg/L 163 5·1 (6·2) 161 7·1 (17·7) 161 5·6 (12·0) 
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α1-acid glycoprotein (AGP), g/L 164 0·6 (0·2) 162 0·6 (0·3) 163 0·7 (0·3) 
Inflammation‡ 
      
CRP >5·0mg/L 52/163 31·9 45/161 28·0 45/161 28·0 
AGP >1·0g/L 9/164 5·5 18/162 11·1 13/163 8·0 
CRP >5·0mg/L OR AGP >1g/L  54/162 33·3 51/161 31·7 50/161 31·1 
Current or recent P falciparum infection§ 0/166 0·0 1/164 0·6 0/165 0·0 
  
AGP: α1-acid glycoprotein; CRP: C-reactive protein; sTfR: soluble transferrin receptor. Values indicate mean (SD), * median [IQR], or † geometric mean (SD), 
‡ proportion in percentage, § As indicated by the presence in whole blood of histidine-rich protein II (HRP-II) antigen of P falciparum, 
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Full listing of all primary and secondary continuous variables at Day 84 
See Supplementary Table 3. The HemoCue results were consistently about 5·0g/L higher 
than the Medonic results, but the relative differences between treatment arms were similar, 
though slightly more pronounced by HemoCue. In the S&T60 group the lower confidence 
interval for the difference against REF was close to the non-inferiority margin at Day 84 (-
2·7g/L [-5·0g/L, -0·5g/L]). In the S&T30 group the lower confidence limit for the difference 
against REF was below the non-inferiority margin (-3·5g/L [-5·7g/L, -1·4g/L]). 
Red cell counts (erythrocytes) were similar across the groups and the lower haemoglobin in the 
S&T groups was accounted for by lower mean corpuscular volume and Mean corpuscular 
haemoglobin as is consistent with their greater iron deficiency. With the exception of plasma 
iron in the S&T60 group, all measures of iron status were worse in the S&T groups than 
REFERENCE. There were no differences in markers of inflammation.  
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Supplementary Table 3: Trial outcome measures at Day 84 of intervention (per-protocol analysis), continuous variables 
Outcome Intervention Group n (%) of 
randomised 
Estimate 
 
SE¶  Effect [95% CI] 
Haemoglobin concentration, g/L 
     
By Medonic analyser REFERENCE 139 (83·7) 110·1 0·8 
 
 
S&T60 131 (79·9) 107·9 0·8 -2·2 [-4·6, 0·1] 
 
S&T30 145 (87·9) 107·4 0·8 -2·7 [-5·0, -0·5] 
By HemoCue field photometer REFERENCE 140 (84·3) 116·6 0·8 
 
 
S&T60 132 (80·5) 113·8 0·8 -2·7 [-5·0, -0·5] 
 
S&T30 147 (89·1) 113·0 0·8 -3·5 [-5·7, -1·4] 
Haematocrit, % REFERENCE 139 (83·7) 30·3 0·2 
 
 
S&T60 131 (79·9) 29·8 0·2 -0·5 [-1·19, 0·13] 
 
S&T30 145 (87·9) 29·6 0·2 -0·7 [-1·3, -0·1] 
Erythrocyte distribution width, % * REFERENCE 139 (83·7) 13·55 0·01 
 
 
S&T60 131 (79·9) 13·70 0·01 1·01 [0·98, 1·04] 
 
S&T30 145 (87·9) 13·67 0·01 1·01 [0·98, 1·04] 
Erythrocyte count, ×1012/L REFERENCE 139 (83·7) 3·7 0·0 
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S&T60 131 (79·9) 3·7 0·0 -0·0 [-0·1, 0·1] 
 
S&T30 145 (87·9) 3·7 0·0 -0·0 [-0·1, 0·1] 
Mean corpuscular volume, fL REFERENCE 139 (83·7) 82·53 0·5 
 
 
S&T60 131 (79·9) 81·45 0·5 -1·08 [-2·6, 0·4] 
 
S&T30 145 (87·9) 81·14 0·5 -1·39 [-2·8, 0·1] 
Mean corpuscular haemoglobin, pg REFERENCE 139 (83·7) 30·0 0·2 
 
 
S&T60 131 (79·9) 29·6 0·2 -0·5 [-1·1, 0·1] 
 
S&T30 145 (87·9) 29·5 0·2 -0·5 [-1·1, 0·1] 
Mean corpuscular haemoglobin concentration, g/L REFERENCE 139 (83·7) 363·9 0·9 
 
 
S&T60 131 (79·9) 362·9 0·9 -1·1 [-3·6, 1·4] 
 
S&T30 145 (87·9) 363·4 0·9 -0·6 [-2·1, 1·9] 
Leukocyte count, ×109/L REFERENCE 139 (83·7) 8·1 0·2 
 
 
S&T60 791 (31·9) 7·9 0·2 -0·2 [-0·6, 0·3] 
 
S&T30 145 (87·9) 7·7 0·2 -0·5 [-0·9, -0·0] 
Lymphocytes, ×109/L † REFERENCE 139 (83·7) 1·86 1·29 
 
 
S&T60 131 (79·9) 1·88 1·30 1·01 [0·95, 1·07] 
 
S&T30 145 (87·9) 1·82 1·25 0·98 [0·93, 1·04] 
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Lymphocytes, % REFERENCE 139 (83·7) 24·7 0·5 
 
 
S&T60 131 (79·9) 25·4 0·5 0·7 [-0·7, 2·1] 
 
S&T30 145 (87·9) 25·5 0·5 0·7 [-0·6, 2·1] 
Granulocytes, x109/L † REFERENCE 139 (83·7) 5·38 1·34 
 
 
S&T60 131 (79·9) 5·11 1·34 0·95 [0·89, 1·02] 
 
S&T30 145 (87·9) 5·00 1·37 0·93 [0·87, 1·00] 
Plasma marker concentrations 
     
Hepcidin, µg/L *† REFERENCE 140 (84·3) 6·26 3·44 
 
 
S&T60 133 (81·1) 3·28 4·17 0·52 [0·37, 0·75]  
 
S&T30 147 (89·1) 2·32 4·74 0·37 [0·26, 0·52]  
Ferritin, µg/L † REFERENCE 139 (83·7) 34·56 1·87 
 
 
S&T60 130 (79·3) 23·07 1·83 0·67 [0·58, 0·77] 
 
S&T30 145 (87·9) 21·42 1·74 0·62 [0·54, 0·71] 
Transferrin, g/L REFERENCE 139 (83·7) 3·1 0·1 
 
 
S&T60 130 (79·3) 3·3 0·1 0·2 [0·0, 0·3] 
 
S&T30 146 (88·5) 3·4 0·1 0·3 [0·1, 0·4] 
UIBC, µmol/L REFERENCE 139 (83·7) 35·5 1·6 
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S&T60 13 (79·9) 42·6 1·6 7·1 [2·6, 11·6] 
 
S&T30 146 (88·5) 49·0 1·6 13·5 [9·1, 17·9] 
Plasma iron, µmol/L REFERENCE 140 (84·3) 32·7 1·3 
 
 
S&T60 131 (79·9) 30·1 1·4 -2·7 [-6·3, 1·0] 
 
S&T30 146 (88·5) 25·2 1·3 -7·5 [-11·1, -3·9] 
Soluble transferrin receptor, mg/L † REFERENCE 140 (84·34) 3·25 1·39 
 
 
S&T60 131 (79·88) 3·95 1·36 1·21 [1·13, 1·31] 
 
S&T30 146 (88·48) 4·03 1·36 1·24 [1·15, 1·33] 
Ferritin index† REFERENCE 139 (83·73) 2·15 1·53  
 S&T60 129 (78·66) 2·91 1·47 1·35 [1·23, 1·49] 
 S&T30 145 (87·88) 3·08 1·48 1·43 [1·31, 1·58] 
C-reactive protein, mg/L REFERENCE 137 (82·5) 4·5 0·5 
 
 
S&T60 129 (78·7) 4·2 0·5 -0·3 [-1·7, 1·0] 
 
S&T30 145 (87·9) 5·2 0·5 0·8 [-0·6, 2·1] 
α1-acid glycoprotein, g/L REFERENCE 140 (84·3) 0·5 0·0 
 
 
S&T60 131 (79·9) 0·4 0·0 -0·0 [-0·1, 0·0] 
 
S&T30 146 (88·5) 0·48 0·0 0·0 [-0·0, 0·1] 
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* Estimates obtained using Tobit regression on the natural-log transformed values, such that at corresponding transformed values, erythrocyte 
distribution width was left-censored at 11·5% and right-censored at 25%, and hepcidin concentration was left-censored at 0·049µg/L (limit of 
detection) and right-censored at 25µg/L with results exponentiated and presented in the table. 
Values indicate mean (SE) or † geometric mean (GSD as geometric standard deviation). Exponentiation of log-transformed variables † yielded 
effect estimates that are expressed as relative differences between geometric means. 
¶ SE = standard error obtained by the Delta method. 
 
 
 
Supplementary Table 4: Trial outcome measures at Day 84 of intervention (per-protocol analysis), categorical variables 
Outcome Intervention Group Prevalence, 
% 
n/N Effect [95% CI]  
Anaemia (haemoglobin concentration <110g/L)     
By Medonic analyser REFERENCE 45·3 63/139 Reference 
 
S&T60 57·3 75/131 11·93 [0·09, 23·77] 
 
S&T30 59·3 86/145 13·99 [2·48, 25·49] 
By HemoCue field photometer REFERENCE 26·4 37/140 Reference 
 
S&T60 28·0 37/132 1·60 [-8·98, 12·19] 
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S&T30 32·0 47/147 5·54 [-4·95, 16·04] 
Hepcidin concentration <2·5µg/L REFERENCE 21·4 30/140 Reference 
 
S&T60 42·1 56/133 20·68 [9·88, 31·48] 
 
S&T30 52·4 77/147 30·95 [20·40, 41·51] 
Mean corpuscular volume <85fL REFERENCE 62·6 87/139 Reference 
 
S&T60 71·8 94/131 9·17 [-1·98, 20·31] 
 
S&T30 74·5 108/145 11·89 [1·17, 22·62] 
Mean corpuscular haemoglobin <27pg REFERENCE 7·2 10/139 Reference 
 
S&T60 10·7 14/131 3·49 [-3·32, 10·31] 
 
S&T30 12·4 18/145 5·22 [-1·65, 12·09] 
Plasma ferritin concentration <15µg/L (not adjusted for 
inflammation 
REFERENCE 8·6 12/140 Reference 
 
S&T60 21·1 28/133 12·48 [4·14, 20·82] 
 
S&T30 21·8 32/147 13·20 [5·07, 21·32] 
Iron deficiency (ferritin <15µg/L CRP <5mg/L) OR (ferritin 
<30µg/L CRP >5mg/L) 
REFERENCE 19·3 27/140 Reference 
 S&T60 30·5 40/131 11·2 [1·0, 21·5] 
 S&T30 41·1 60/146 21·8 [11·5, 32·1] 
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Iiron deficiency anaemia (Hb <110g/L ferritin < 15µg/L 
CRP <5mg/L) OR (Hb <110g/L ferritin < 30µg/L CRP 
>5mg/L & ferritin index >2) 
REFERENCE 58·6 82/140 Reference 
 S&T60 87·2 116/133 28·6 [18·7, 38·6] 
 S&T30 89·1 131/147 30·5 [21·0, 40·1] 
Plasma iron concentration <8·95µmol/L REFERENCE 3·6 5/140 Reference 
 
S&T60 3·0 4/133 -0·56 [-4·79, 3·66] 
 
S&T30 6·8 10/147 3·23 [-1·87, 8·33] 
Transferrin saturation (TSAT) <16% REFERENCE 5·0 7/139 Reference 
 
S&T60 15·3 20/131 10·23 [3·08, 17·38] 
 
S&T30 19·9 29/146 14·83 [7·40, 22·25] 
Iron-deficient erythropoiesis (sTfR concentration >4·4mg/L) REFERENCE 14·3 20/140 Reference 
 
S&T60 38·2 50/131 23·88 [13·74, 34·02] 
 
S&T30 41·8 61/146 27·50 [17·62, 37·37] 
Inflammation, CRP ≥5·0mg/L or AGP >1·0g/L  REFERENCE 33·6 46/137 Reference 
 
S&T60 23·3 30/129 -10·32 [-21·08, 0·43] 
 
S&T30 32·4 47/145 -1·16 [-12·14, 9·82] 
Plasma ferritin <15µg/L and AGP <1·0g/L  REFERENCE 8·7 12/138 Reference 
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S&T60 21·1 28/133 12·36 [3·98, 20·73] 
 
S&T30 22·1 32/145 13·37 [5·15, 21·60] 
Plasma ferritin <15µg/L and CRP <5·0mg/L or AGP 
<1·0g/L  
REFERENCE 10·6 10/94 Reference 
 
S&T60 21·4 22/103 10·72 [0·65, 20·80] 
 
S&T30 25·0 25/100 14·36 [3·83, 24·89] 
Current or recent P. falciparum infection‡ REFERENCE 1·4 2/140 Reference 
 
S&T60 2·3 3/133 0·83 [-2·37, 4·03] 
  S&T30 3·4 5/147 1·97 [-1·56, 5·50] 
‡ As indicated by the presence in whole blood of histidine-rich protein II (HRP-II) antigen of P. falciparum 
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Supplementary table 5: Reported side effects, adverse and serious adverse events 
 
Outcome 
 
Reported side effects 
Intervention 
group 
Observed 
counts per 
1000 person- 
weeks 
Cases/Person-
weeks 
Effect [95% CI] 
Nausea REFERENCE 11 21/1974 
 
 
S&T60 14 27/1906 1·4 [0·64, 2·86]  
S&T30 7 14/2009 0·7 [0·29, 1·51]      
Dizziness REFERENCE 31 62/1974 
 
 
S&T60 40 76/1906 1·3 [0·8, 2·0]  
S&T30 16 32/2009 0·5 [0·3, 0·9]      
Constipation REFERENCE 13 26/1974 
 
 
S&T60 22 42/1906 1·7 [0·8, 3·4]  
S&T30 14 28/2009 1·1 [0·5, 2·3]      
Black stool REFERENCE 5 9/1974 
 
 
S&T60 2 3/1906 0·3 [0·1, 1·4]  
S&T30 3 6/2009 0·7 [0·2, 2·0]      
Stomach ache REFERENCE 41 81/1974 
 
 
S&T60 43 82/1906 1·0 [0·7, 1·6]  
S&T30 29 58/2009 0·7 [0·5, 1·1]      
Fatigue REFERENCE 11 21/1974 
 
 
S&T60 16 31/1906 1·5 [0·7, 3·2]  
S&T30 8 16/2009 0·8 [0·3, 1·8] 
     
Adverse events     
Cough, cold and chest pain REFERENCE 11 20/1902 
 
 
S&T60 10 19/1861 1·0 [0·5, 1·8]  
S&T30 9 18/1945 0·9 [0·5, 1·7]      
Diarrhoea REFERENCE 3 5/1902 
 
 
S&T60 2 3/1861 0·6 [0·1, 2·6]  
S&T30 2 4/1945 0·8 [0·2, 2·9]      
Fever REFERENCE 3 5/1902 
 
 
S&T60 2 4/1861 0·8 [0·2, 3·0]  
S&T30 5 9/1945 1·8 [0·6, 5·3]      
General body pain # REFERENCE 4 7/1902 
 
 
S&T60 3 5/1861 0·7 [0·2, 2·5]  
S&T30 4 8/1945 1·1 [0·4, 3·4]      
Headache # REFERENCE 11 21/1902 
 
 
S&T60 9 17/1861 0·8 [0·4, 1·6]  
S&T30 12 24/1945 1·1 [0·6, 2·1]      
Heartburn # REFERENCE 2 3/1902 
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S&T60 2 3/1861 1·0 [0·2, 5·7]  
S&T30 6 11/1945 3·6 [0·9, 14·8]      
Lower abdominal pain # REFERENCE 20 38/1904 
 
 
S&T60 16 30/1861 0·8 [0·5, 1·3]  
S&T30 15 30/1945 0·8 [0·5, 1·3]      
Toothache REFERENCE 6 11/1902 
 
 
S&T60 2 4/1861 0·4 [0·1, 1·2]  
S&T30 3 6/1945 0·5 [0·2, 1·4]      
Urinary tract infection or dysuria REFERENCE 9 17/1902 
 
 
S&T60 10 18/1861 1·1 [0·6, 2·1]  
S&T30 9 17/1945 1·0 [0·5, 1·9]   
  
 
Vomiting REFERENCE 1 2/1902 
 
 
S&T60 2 3/1861 1·5 [0·3, 9·2]  
S&T30 1 2/1945 1·0 [0·1, 6·9]      
Gastritis # REFERENCE 2 3/1902 
 
 
S&T60 4 7/1861 2·4 [0·6, 9·8]  
S&T30 2 4/1945 1·3 [0·3, 6·2]      
Nausea REFERENCE 1 1/1902 
 
 
S&T60 1 1/1861 1·0 [0·1, 16·4]  
S&T30 1 2/1945 2·0 [0·2, 21·6]      
Others REFERENCE 18 34/1902 
 
 
S&T60 19 35/1861 1·1 [0·7, 1·7]  
S&T30 20 40/1945 1·2 [0·7, 1·8] 
     
Serious adverse events¤     
Death REFERENCE 0 NA 
 
 
S&T60 0 NA NA  
S&T30 0 NA NA      
Life-threatening REFERENCE 0 NA 
 
 
S&T60 0 NA NA  
S&T30 0 NA NA      
Hospitalisation Required or 
Prolonged 
REFERENCE 3 1/1904 
 
 
S&T60 10 3/1861 1·5 [0·2, 12·3]  
S&T30 0 0/3255 0·0 [0·0]      
Congenital anomally/birth defect REFERENCE 0 NA 
 
 
S&T60 0 NA NA  
S&T30 0 NA NA      
Miscarriage REFERENCE 20 4/1904 
 
 
S&T60 31 5/1861 1·5 [0·2, 12·3]  
S&T30 4 1/1945 0·2 [0·0, 2·5] 
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# used Negative Binomial regression, otherwise Poisson regression used 
¤ Calculated using: observed counts per 10,000 person weeks 
 
Supplementary Figure 3 
Variation in plasma hepcidin through the course of the intervention and change over time of 
hepcidin and haemoglobin concentration, by intervention group (per protocol analysis) 
 
 
 
 
     
Stillbirth # REFERENCE 13 4/1904 
 
 
S&T60 20 6/1861 1·6 [0·4, 5·6]  
S&T30 15 5/1945 1·2 [0·3, 4·5] 
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Legend:  
Hepcidin concentration (A) was analysed by Tobit regression to account for right-censored values (see 
text). Mean values and 95%CI. P-values for time × intervention interaction effects: S&T60 versus REF, P = 
0·002 and S&T30 versus REF, P < 0·001.  Haemoglobin concentration measured by Medonic analyser (B): 
S&T60 versus REF, P = 0·064 and S&T30 versus REF, P = 0·001. Haemoglobin concentration measured 
by HemoCue photometer (C): S&T60 versus REF, P = 0·048 and S&T30 versus REF, P < 0·001. 
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Supplementary Figure 4 
Sentinel bacterial growth rates at Day 84 according to whether pregnant women received iron or 
placebo 3h prior to blood draw 
 
Legend:  
Ex vivo bacterial growth rates in serum from Day 84. Blue = REF, red = S&T60, green = S&T30. On this 
final day of the study pregnant women received multiple micronutrients with iron (+) or without iron (-) 
according to their hepcidin level measured 7 days previously except in REF who all received multiple 
micronutrients with iron as per the protocol. *** = P<0·001, NS = not significant. In the women receiving iron 
there was no difference in mean growth between the three intervention groups. 
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Chapter 6: Summary discussion 
 
6.1 Current approaches to combatting ID and anaemia in pregnancy 
The World Health Organization (WHO) currently recommends daily supplementation with 30 - 60mg 
elemental iron (as ferrous salt) throughout pregnancy, starting as early in pregnancy as possible, 
with a preferred daily dose of 60mg of elemental iron in settings where anaemia in pregnant women 
is a severe public health problem (prevalence of 40% of higher) [132].  
 
6.2 Evidence for efficacy of current approaches 
Universal antenatal iron supplementation provides maternal and neonatal health benefits in iron-
deficient pregnant women, with the balance between benefits and risks probably being more 
favourable in low-income countries than in high-income countries. The maternal health benefits 
include: reduction in the risk of anaemia at term, reduction in risk of pre-term delivery and reduced 
risk of transfusion being required by the mother at term, and a reduction of the risk of maternal 
haemorrhage thus increasing the chances of survival [153].  The neonatal health benefits would 
include: increased birthweight by as much as 150g [154]), decreased risk of low birthweight by 19%, 
increased gestational duration leading to decreased risk of prematurity, increased neonatal length, 
and improved neonatal iron stores at one month postpartum [153].  There is evidence to suggest 
that supplementation with iron and folic acid for pregnant women in low and middle-income 
countries should be expanded with other micronutrients as multiple micronutrient deficiencies are 
common among women of reproductive age and can impair the utilisation of iron [149].   
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6.3 Limitations of current approaches 
However, there are uncertainties about the appropriate dosage regimen, particularly the optimal 
intervals and doses for iron supplementation. As compliance or adherence is known to be low in 
least developed countries [142, 155], reducing the intake of supplemental iron can avoid self-limiting 
and dose-dependent adverse effects in the gastrointestinal tract (constipation, nausea, vomiting, 
and epigastric discomfort) that limit adherence [156]. There are also concerns, however, that iron 
supplementation can predispose to maternal Plasmodium infection [138], bacteraemia [157], 
haemoconcentration (haemoglobin concentration exceeding 130g/L) [7], gestational diabetes [158, 
159] and preeclampsia [134, 160]. 
6.4 Alternative approaches for iron supplementation  
There is now some evidence that smaller doses of 30mg iron daily could achieve similar results as 
the daily 60mg iron [49].   A Cochrane review on the treatments of iron deficiency anaemia in 
pregnancy [147] indicated that daily low dose iron supplementation may be effective at treating 
anaemia in pregnancy with fewer gastrointestinal side effects compared with higher doses. Weekly 
Iron-Folic Acid Supplementation (WIFS) is an approach that can be effective for ensuring adequate 
iron status of women, particularly before pregnancy and during the first trimester in communities 
where food-based strategies are not yet fully implemented or effective [161]. Although efficacy in 
reducing anaemia is low it may be a feasible alternative to daily iron supplementation among those 
pregnant women who are not anaemic and have adequate antenatal care [162].  
Iron deficiency is known to also occur as a result of the intake of diets that are monotonous, low in 
animal food sources, and primarily based on unrefined cereals, grains and legume seeds. Although 
these foods have reasonable iron content, they also contain high concentrations of phytate that 
hinder the absorption and utilisation of the iron [153]. 
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Therefor, food fortification has been shown to reduce anaemia among women and children  [163]  
and in countries with flour fortification, each year of flour fortification is associated with a 2.4% 
decrease in anaemia prevalence among non-pregnant women [164].  
6.5 Could a screen-and-treat approach be better than a universal daily iron 
supplementation? 
We hypothesised that a hepcidin-guided screen-and-treat approach to iron supplementation would 
be non-inferior to the WHO-recommended universal daily supplementation and evaluated this in a 
RCT with haemoglobin concentration at the end of the intervention as the primary endpoint. 
6.6 Developing the diagnostic threshold 
In the first study, we set out to define a hepcidin cut off value based on the analysis of plasma from 
395 pregnant women participating in the ENID study [165] with samples available for 3 time points 
(14 weeks, 20 weeks and 30 weeks gestation). We established <2.5µg/L as a threshold for ‘ready 
and safe’ to receive iron [166]. We noted in this study that hepcidin is a good indicator for detecting 
iron deficiency in pregnancy and believed that the diagnostic cut off was valid and worked well as 
the sensitivity for detection was greater than 80%. Although hepcidin does decrease from the 
second and third trimester and correlates well with iron deficiency in pregnancy, it can become 
undetectable by the third trimester [167] and it is known that undetectable serum hepcidin does 
enable dietary iron transfer from mother to foetus [123].  However, we observed in our study that a 
reduction in iron stores (ferritin, sTfR and total body iron) that occurred between 20 and 30 weeks of 
pregnancy was not supported by a further reduction in hepcidin concentration.  This may suggest 
that other factors other than iron deficiency alone may have played a role in the smaller reduction of 
hepcidin concentration.    
6.7 Testing the screen-and-treat approach 
In the second study, we identified 527 pregnant women with gestational age 14–22 weeks and 
enrolled/randomised 498 participants to the 3 arms from June 2014 to March 2016 in rural Gambia. 
The prevalence of anaemia among pregnant women in this setting is high (over 50%) and this is 
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consistent with national prevalence of 67.9% [168]. The screen-and-treat threshold resulted in a 
50% reduction in iron administration and, in this respect, was highly successful in setting up a 
meaningful trial. In the per protocol analysis, the mean haemoglobin concentration difference was 
assessed at Day 84 and the lower confidence interval used to determine non-inferiority. The data 
from the trial indicated that hepcidin-guided screen-and-treat approaches with either 60mg or 30mg 
iron as ferrous fumarate using mean haemoglobin difference remained marginally within the non-
inferiority margin of -5.0g/L, but performed worse than the daily supplementation (screen-and-treat 
60 (-4.6g/L) and for screen-and-treat 30 (-5.0g/L)). The results of the intention to treat analysis were 
similar. Whilst the prevalence of anaemia (haemoglobin <110g/L) was reduced from 58.2% to 
45.3% in the Reference group, the prevalence increased in both the screen-and-treat 60 and 
screen-and-treat 30 groups (52.2% to 57.3%) and (52.8% to 59.3%), respectively.  
Additionally, improvement in haemoglobin was  low as the effectiveness of the supplementation 
yielded a mere 3.3g/L, and a 13% reduction in anaemia prevalence in the Reference group. The 
modest intervention effect on haemoglobin has been shown by others previously [7, 153].  
The most significant contributor to the onset of anaemia worldwide is iron deficiency [1] and WHO 
estimates that iron deficiency anaemia affects almost half of the world’s pregnant women and pre-
school children with a prevalence of over 65% in Africa and Asia, and that it causes (directly or 
indirectly) one fourth of all maternal deaths [2].  Our results clearly show that mean measures of iron 
deficiency (hepcidin, ferritin) were significantly worse in the screen-and-treat groups than the 
Reference group.  Other iron markers such as plasma iron, transferrin, soluble transferrin receptor 
also show similar results while unsaturated iron binding capacity were higher. The corresponding 
prevalence of iron deficiency determined by ferritin, transferrin saturation, soluble transferrin 
receptor, increased in the screen-and-treat groups. Prevalence of iron deficiency anaemia was also 
higher in the screen-and-treat groups. 
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Although the hepcidin-guided approach was able to halve the iron exposure in the two screen-and-
treat groups, where screen-and-treat 60 group received 45.2% weeks of iron in the intervention 
period and screen-and-treat 30 received 52.6%, our data show that for hepcidin as a marker of 
‘ready to receive’ iron, prevalence was higher in the screen-and-treat 60  group (41.7%), screen-
and-treat group 30 (52.4%), than the Reference group (21.4%). Apart from our results showing that 
the approaches were able to half the amount of iron received by pregnant women, there were no 
advantages for the screen and treat approaches.  The approaches may not have worked as 
anaemia has many causes which are not amenable to iron therapy. In Africa, only 44% of anaemia 
cases are attributed to iron deficiency and are amenable to iron supplementation.  A higher 
threshold (above 2.5µg/L) may have increased the efficacy but this would have increased the 
amount of iron given to the pregnant women in the screen-and-treat groups, and reducing the 
overall iron given to those who did not need them was one of our objectives. On the other hand, a 
study among non-pregnant Indian women has shown a cut off ≤4.5µg/L was associated with higher 
diagnostic likelihood for IDA [169].  Although there were no differences between the groups for 
inflammation (CRP and AGP), and for illnesses, our threshold could have failed to fully capture the 
effect of low grade inflammation as seen by our group in Gambian children [170].  
Adherence in our study was high, exceeding 80% in all three groups as seen elsewhere [171].  This 
was however achieved as the women were aware that their intake of the capsules were being 
monitored.  However, other studies have shown that adherence could be low in areas where the 
rate of iron-folic acid supplementation during pregnancy is relatively low, there is poor counselling 
on the use of iron and folic acid intake, low promotion of its benefits, inadequate encouragement for 
early antenatal care attendance and inadequate general health promotion on anaemia prevention 
[172].  
Much has been made of the negative contribution of iron and folic acid supplementation on the 
occurrence of illnesses and side effects during pregnancy. However, contrary to the belief that 
women stop taking iron tablets mainly due to negative side effects, only about one-third of women 
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reported that they experienced negative side effects in this study. The major barrier to effective 
supplementation programmes is inadequate supply, counselling and distribution of iron tablets, 
difficult access and poor utilization of prenatal health care services, beliefs against consuming 
medications during pregnancy, and in most countries, fears that taking too much iron may cause too 
much blood or a big baby, making delivery more difficult [3]. Our data show that reported illnesses 
and side effects were similar between the Reference daily supplemented group and the screen-and-
treat 60 and slightly lower in the screen-and-treat 30 group. The reduction in the episodes of side 
effects reported in the screen-and-treat 30 group may have been as a result of them receiving 
reduced doses of iron. 
The frequency of adverse events (respiratory infections, diarrhoea, fever, general body pain, urinary 
tract infection, vomiting, nausea, headache, toothache, heart burn) and serious adverse events 
(death, life threatening, prolong hospitalisation, congenital anomaly/birth defect, miscarriage, 
stillbirth) were similar between the groups. There were no reported deaths or life-threatening 
situations. 
To further assess safety of the iron administration, ex vivo growth of three bacteria (Escherichia coli, 
Salmonella enterica and Staphylococcus aureus) were done. Growth was seen to be faster after the 
commencement of the study but there were no differences between the treatment groups on Days 
14 and 49. However, on Day 84 when supplements were given 3 hours before blood draw, the 
Reference group supported a faster growth than the screen-and-treat 30 group for E. coli and S. 
aureus, and for the screen-and-treat 60 only for E. coli. We found no difference in bacterial growth 
across intervention groups among women who received iron 3 hours prior to the blood draw, and 
significantly lower growth in those in the screen-and-treat groups who did not receive iron.  
Further more, we asses growth of malaria parasites in fresh RBCs and found growth to be 
suppressed at baseline (compared to the non-anaemic controls used in the assay). Growth was 
then greatly stimulated at Day 14 and gradually declined to Day 84. Although Ex vivo malarial 
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parasite growth in erythrocytes were increased by iron administration, gowtth did not differ by 
treatment group. 
6.8 Potential explanation for why screen-and-treat did not work 
Anaemia can be caused by other factors (including inflammation) besides iron deficiency.   
Inflammation has been shown to upregulate hepcidin which can block iron absorption leading to a 
poor respond to iron treatment [121].  On the other hand, iron interventions have been shown to 
prevent 20 – 50% of the prevalence of anaemia in pregnant women [173, 174]. Some of the other 
potential explanations are contained in the limitations of the study below. 
Although the two screen-and-treat approaches were found to be non-inferior to the daily iron 
supplementation recommended by WHO, the daily iron supplementation performed better with 
regards to anaemia and other iron markers including hepcidin, ferritin, transferrin saturation and 
soluble transferrin receptor.  We were therefore unable to demonstrate support for screen-and-treat 
approach to iron supplementation based on hepcidin concentration <2.5µg/L in pregnant Gambian 
women. 
6.9 Study limitations 
One of the limitations of the main study is the quantification of hepcidin as a single measure to allow 
for the availability of the hepcidin results within 24 hours after blood is collected.  When hepcidin 
results were not available for a particular week, results of the previous week were used. This was 
done due to cost and the need for the availability of the results to enable allocation of treatment.  
The availability of an affordable and reliable hepcidin-based PoC test that was rapid enough to 
inform our iron treatment before an individual’s iron status significantly alters [175] would have 
enabled us screen more frequently.  
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In the determination of hepcidin cut off <2.5µg/L, we priotised sensitivity over specificity as a trade-
off inorder not to miss pregnant women who needed iron and were ready to utilise it.  Ideally, we 
could have prioritised both. 
Gestational age at enrolment was assessed by means of reported first date of last menstrual period 
and by fundal height estimation conducted by experience midwives.  The use of the above methods 
may not be as accurate as  say estimation using ultra sound.  This has sometimes led to the under-
estimation of gestational age and this may have resulted to the delivery by women before they 
finished the study.  Although this did not affect the results, the highest contributor to the dropout rate 
was women delivering during the study period as seen in the CONSORT diagram. 
We could have included a fourth arm of 30mg iron daily to assess the outcome of reduced iron use 
(30mg iron daily) compared to 60mg daily.  The 30mg daily may have been equally efficacious 
compared to the 60mg daily in this setting. Reveiz et al [147] concluded that daily low-dose iron 
supplements may be effective at treating anaemia in pregnancy with fewer gastrointestinal side 
effects compared with higher doses. 
6.10 Public health implications and policy recommendations 
Our study (Paper II-chapter 4) demonstrated that hepcidin performs well as a diagnostic test for iron 
deficiency in pregnant Gambian women and has enabled us to propose putative cut offs for when 
the pregnant woman is ready and it is safe for her to receive iron. Kanuri et al [169] found hepcidin 
to be a valuable diagnostic tool for IDA among Indian women.  These results should however be 
validated with a large-scale trial to increase the degree of certainty as well as looking at the cost 
implication in order to support the use of hepcidin as an assessment indicator for iron deficiency that 
will  complement the use of ferritin as a conventional marker.  
Our main trial (Paper III-chapter 5) has shown that it is possible to replace iron and folic acid with a 
multiple micronutrient supplement containing 15 vitamins and minerals into the routine national 
supplementation services in The Gambia. 
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Women receiving daily 60mg iron are less likely to be anaemic and iron deficient and therefore the 
WHO recommendation of daily iron folic acid supplementation of pregnant women where anaemia 
is a public health problem should be maintained. 
6.11 Future research needs 
On the basis of our findings, coupled with available evidence that current approaches and 
interventions to combat iron deficiency and anaemia in pregnancy still have somewhat 
limited efficacy, future research may look into: 
i. Testing the efficacy of 30mg iron daily (lower dose with increased bioavailability) against 
60mg daily in developing countries as demonstrated by Milman et al, 2014 (for 25mg iron) 
among pregnant women in advanced country setting [176]. This may be beneficial to 
pregnant women who are iron replete and may not need or will not benefit from consuming 
60mg elemental iron daily. As shown from our data that the risk of self-reported illnesses and 
side effects was lower in the reduced dose of 30mg (screen-and-treat) than the reference 
daily 60mg supplementation, goes to show that a reduced dose may be beneficial for 
pregnant women with replete iron status. 
ii. The suggestions that the optimal pregnancy outcomes in terms of birth weight and pre-term 
labour occur at a mid-pregnancy haemoglobin of between 95 and 105g/l [85], which is 
actually lower than the current WHO definition of anaemia (haemoglobin cut off of <110g/L). 
Per our data, the prevalence of anaemia was 58.2% for the Reference arm at baseline 
(haemoglobin cut off <110g/L).  We noted that, this could have been 41.0% (a difference of 
17.2%) if the cut off was to be haemoglobin <105g/L from the second trimester as suggested 
by the CDC [177, 178]. It would be important to investigate as to how much of this lower 
prevalence is actually due to ID and therefore iron supplementation of this may be more 
efficacious.  
iii. Even though we have not seen significant differences in inflammation markers (CRP and 
AGP) and reported illnesses, we may have failed to capture low-grade inflammation as seen 
   
 
Page 141 of 185 
 
in children [20]. Therefore, it may be beneficial for future research to investigate the role of 
infections and inflammation on hepcidin variation in pregnancy. 
iv. The development and validation of a low cost hepcidin-based PoC test kit for iron deficiency 
in pregnancy with reference standards using ferritin, sTfR and TSAT. This is important as the 
physiological adaptation to iron needs and the lower loss of iron due to the cessation of 
menses during pregnancy, may potentially enhance the vulnerability to high iron intakes in 
iron-replete individuals [179], and therefore the need to accurately assess ID. Serum 
hepcidin as a key regulator of iron homeostasis, is an important biomarker because its levels 
determines how well oral iron is absorbed, with low hepcidin levels indicating both a 
requirement for iron and the body’s ability to utilise it [119, 180]. Serum ferritin is one of the 
few biochemical indices of which low levels reflect depleted iron stores [94, 95] but it is 
known to be raised by infection and inflammation as it is an acute phase protein and thus 
has very high false negative rates in least developed countries [96]. Similar problems also 
arise with the other commonly used iron status indicators as summarised in Table 2 above.  
 
6.12 How well was the overall aim of the study met? 
The overall aim was to find a better and safer way to administer iron supplementation to pregnant 
women through screen-and-treat approaches among rural Gambian women.  We established a 
hepcidin threshold to guide the screen-and-treat approaches.  However, the hepcidin-guided 
screen-and-treat approaches were not as efficacious in combatting anaemia, ID and IDA as the 
60mg WHO recommended daily iron supplementation for where anaemia in pregnant women is a 
severe public health problem, and the approaches had no added advantage than universal daily 
iron supplementation in terms of adherence, side effects or safety outcomes. We therefore suggest 
that the current WHO policy for iron supplementation for pregnant women be continued in this 
setting.  Therefore, the objective of setting up a study for the PhD to test the efficacy of a screen-
and-treat approach to combat ID and anaemia was successfully achieved.     
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7 Appendices 
 
Appendix 1: Ethics approval, Gambia 
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Appendix 2: Ethics approval from The LSHTM 
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Appendix 3: Participant information sheet and consent form 
PARTICIPANT INFORMATION SHEET               
Version 2.0  Date 14.11.2014   
 
Study Title: : A double blind randomised controlled trial comparing standard dose of iron 
supplementation for pregnant women with two screen-and-treat approaches 
using hepcidin as a biomarker for ready and safe to receive iron. 
 
SCC: 1357 Protocol:  
 
Sponsor: MRC-ING 
What is informed consent?  
You are invited to take part in a research study. Participating in a research study is not the same as 
getting regular medical care. The purpose of regular medical care is to improve one’s health. The 
purpose of a research study is to gather information that may be useful in future for the whole 
population. It is your choice to take part and you can stop any time. 
 
Before you decide you need to understand all information about this study and what it will involve. 
Please take time to read the following information or get the information explained to you in your 
language. Listen carefully and feel free to ask if there is anything that you do not understand. Ask 
for it to be explained until you are satisfied. You may also wish to consult your spouse, family 
members or others before deciding to take part in the study. 
 
If you decide to join the study, you will need to sign or thumbprint a consent form saying you agree 
to be in the study. You will receive a copy of this.  
Why is this study being done?  
Anaemia in pregnancy in The Gambia is a major public health problem with over 70% of pregnant 
women affected.  WHO recommends iron supplementation for all pregnant women using 60 mg iron 
and 400 ug folic acid daily (red tablets given at antenatal clinics) to prevent and manage anaemia.  
This is known to reduce anaemia, however, recent studies have indicated that giving iron to those 
who do not need it can pose risks to pregnant women.  The aim of this study is to evaluate a 
screen-and-treat approach (who needs or does not need iron and at what time) using hepcidin (a 
body hormone) to assess this.  We believe that proper assessment and the giving of iron at a lower 
dose will improve safety and tolerability. 
 
The results of the study will be made available to your community. 
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What is the new vaccine/drug? 
What we are using for this study is not a new drug but a nutritional supplement that has been 
recommended and is being used for the prevention of anaemia. 
What does this study involve? 
Once you are enrolled in this study you will be registered.  You will be asked to provide a 7 ml 
venous blood (Day 0 below). You will then be assigned by chance to one of 3 study groups to either 
receive: a) a multiple micronutrient supplement with 60 mg iron daily or b) multiple micronutrient 
supplement with 60 mg iron when hepcidin analysis indicate it is safe to be given iron or c) multiple 
micronutrient supplement with 30 mg iron when hepcidin analysis indicate it is safe to be given iron. 
Please note that, your participation in this study will in no way affect your attendance of Government 
antenatal services. 
 
As a participant of this study, field workers will be inviting you every week to screen you using a 
finger prick blood sample and to provide you with a 7 day supply of your supplements. You will also 
be provided with a long lasting insecticide-treated bed net. 
 
 In order to facilitate analysis in this study you will be asked to provide 7 ml venous blood at 4 
different times (Day 0, 14, 49 and day 84) within the 12 weeks period of the study.  
 
You will be tested for malaria every week (using the finger prick blood sample as described above) 
and, if at any day you are found to have malaria, you will be asked for a further 2 ml of blood. This 
will allow us to conduct some further tests in relation to iron and malaria. 
 
In case the investigator discovers you are sick and decides that you cannot participate in the study 
because of that, you will receive immediate care at the study site and then be referred to the 
appropriate health facility.  
 
If the research study needs to be stopped, you will be informed and you will have your normal 
medical care. 
What will happen to the samples taken in this study? 
The blood samples collected will be analysed in Keneba to get answers but part of it will be stored 
for further analysis. Part of the stored blood will also be used for infection and genetic analysis.  
Some of the blood samples will be transferred to a laboratory overseas for analysis because we 
don’t have the equipment required for measuring all of the factors we are investigating in The 
Gambia. 
 
What harm or discomfort can you expect in the study? 
There will be minimum discomfort during the collection of finger prick and venous blood samples.  
The risk of iron over dosage is minimised as the reference arm of this study is a standard 
government practice and the intervention is an overall lower dosage. 
 
What benefits can you expect in the study?  
Benefits will include study participants having access to basic medical services on top of what is 
provided by the RCH.  Participants will also benefit from weekly monitoring by qualified field workers 
where anaemia can be detected.  Malaria can also be diagnosed and managed immediately.  
Participants will be followed-up by the research team even after the 12 weeks intervention to assess 
their pregnancy outcome and the health of their babies.  
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Will you be compensated for participating in the study? 
You will not get paid for participation, but you will get either transport by MRC or get the costs for 
the transport reimbursed.  
Are there other products or treatment? 
No. 
What happens if you refuse to participate in the study or change your mind later? 
You are free to participate or not in the study and you have the right to stop participating at anytime 
without giving a reason. This will not affect the medical care that you would normally receive.  
 
In case you decide to withdraw your participation during the study, we will not work on your samples 
without your permission, but any information already generated from the samples will be kept. The 
study doctor may also ask for tests for your safety.  
 
Should any new information become available during the study that may affect your participation, 
you will be informed as soon as possible. 
If you are injured in the study what compensation will be available?  
We will be responsible to provide for treatment caused by the research study. If you have an 
unwanted reaction, we will treat you or refer you as needed. 
If medical treatment is required as an emergency, please refer to your health centre or clinic and 
contact the field worker who gave his/her telephone number to you or contact Mr. Amat Bah, 
9901696 or Dr. Rita Wegmuller, 9963991.  
How will personal records remain confidential and who will have access to it? 
All information that is collected about you in the course of the study will be kept strictly confidential. 
Your personal information will only be available to the study team members and might be seen by 
some rightful persons from the Ethics Committee, Government authorities and sponsor. 
Who should you contact if you have questions? 
If you have any queries regarding the study you can contact Mr. Amat Bah, 9901696 or Dr. Rita 
Wegmuller, 9963991, and you can always call the personal numbers of the study staff given to you. 
If you have any concerns you can also contact staff at your health centre or clinic. 
 
Please feel free to ask any question you might have about the research study. 
Who has reviewed this study?  
This study has been reviewed and approved by a panel of scientists at the Medical Research 
Council and the Gambia Government/MRC Joint Ethics Committee, which consists of scientists and 
lay persons to protect your rights and wellbeing. 
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             CONSENT FORM                                          
Participant Identification Number: |__|__|__|__|__|__|__|__|__|__|__|__| 
  
 (Printed name of participant) 
   I have read the written information OR 
   I have had the information explained to me by study personnel in a language that I understand 
and I confirm that my choice to participate is entirely voluntarily, 
 confirm that I have had the opportunity to ask questions about this study and I am satisfied with 
the answers and explanations that have been provided, understand that I grant access to data 
about me to authorised persons described in the information sheet, have received time to 
consider to take part in this study, agree to take part in this study.  
 
Tick as appropriate 
I agree to further research on my samples as described  
in the information sheet 
Yes  No  
Participant’s signature/ 
thumbprint* 
    
   Date (dd/mmm/yyyy) Time (24hr) 
    
Printed name of impartial 
witness* 
 
Signature of impartial 
witness* 
    
 
  Date (dd/mmm/yyyy) Time (24hr) 
Printed name of person 
obtaining consent 
 
 
I attest that I have explained the study information accurately in ______________________ 
and was understood to the best of my knowledge by the participant and that he/she has 
freely given consent to participate *in the presence of the above named impartial witness 
(where applicable).  
 
Signature of person 
obtaining consent    
   Date (dd/mmm/yyyy) Time (24hr) 
* Only required if the participant is unable to read or write. 
A copy of this informed consent document has been provided to the participant. 
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Appendix 4: Investigational products or intervention  
We administered three investigational products as nutrition supplements:  
UNIMMAP with 60 mg iron  
UNIMMAP with 30 mg iron   
UNIMMAP with 0 mg iron. 
Description of product or intervention  
The nutritional supplement used in this trial is the UNICEF/WHO/UNU international multiple 
micronutrient preparation (UNIMMAP). All formulation also contain 400 ug folic acid and 14 other 
micronutrients (Table-------).  The UNIMMAP supplement has been used safely in other pregnancy 
trials [181].  
Formulation, packaging and labelling  
The formulation was produced by DSM South Africa under GMP conditions where was dosed into 
gelatin capsules, packed in tubs. The labelling included a statement that ‘trial medications are only 
for use of trial participant’. 
Table ---: Intervention product - Formulation based on UNU/UNICEF/WHO supplement called 
UNIMMAP 
Micronutrients Dose/day 
Vitamin A (ug RE) 800  
Vitamin D (IU) 200 
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Vitamin E (mg) 10 
Thiamine (mg) 1.4  
Riboflavin (mg) 1.4  
Niacin (mg) 18  
Folic acid (ug) 400  
Vitamin B6 (mg) 1.9 
Vitamin B12 (ug) 2.6 
Vitamin C (mg) 70  
Zinc (mg) 15  
Iron (mg) 60 or 30 or 0 
(placebo) 
Iodine (ug) 150  
Selenium (ug) 65  
Copper (mg) 2  
 
Product storage and stability  
We stored the products under controlled conditions (in an air-conditioned storage house at around 
20°C) at the MRC Keneba. The product is stable for 18 months if kept under these conditions.  
Dosage, preparation and administration of investigational product 
or intervention  
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Each participant received 1 daily dose of the supplement which corresponds to 1 capsule per day. 
Each week field workers visited the study participants and distributed the respective weekly supply 
(7 capsules) to each participant.  The participants were instructed to take 1 capsule a day with a bit 
of water or a drink. Each time the field workers distribute the new weekly supply of capsules they 
accounted for the number of capsules consumed/not consumed from the previous week in order to 
check for compliance.  
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Appendix 5: Safety considerations and oversight 
This trial was overseen by a Data Safety Monitoring Board (DSMB); chaired by Dr Jay Berkley, 
KEMRI Wellcome Trust, Kilifi, Kenya): to safeguard the interests of trial’s participants, investigators 
and sponsor; to assess the safety and efficacy of the trial’s intervention, and to monitor the trial’s 
overall conduct, and protect its validity and credibility.  The DSMB was assisted by a Trial monitor 
and a Trial Steering Committee (TSC). 
The DSMB undertook interim review of the trial’s progress by:  
• assessing data quality, recruitment and losses to follow-up 
• monitoring compliance with the protocol by participants and investigators 
• monitoring evidence for treatment differences in the main outcome measures and for treatment 
harm 
• recommending action whether the trial should continue to recruit or follow-up  
• recommending or advising on any major changes or modifications to the protocol 
• suggesting additional data analyses 
• assessing the impact and relevance of any external evidence provided 
The DSMB was additionally responsible for reviewing all Serious Adverse Events (SAE) defined 
below. 
Methods and timing for assessing, recording, and analysing safety parameters 
We conducted the trial according to Good Clinical Practice (GCP) principles (ref: MRC DMID 
Protocol Tepmplate_Att1_V3_Protocol Template_SOP-CTS004) (Declaration of Helsinki, Adopted 
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by: 64th WMA General Assembly, Fortaleza, Brazil, October 2013). The DSMB determined how 
they were to monitor the data and safety interest of the participants.  The DSMB also determined 
how and the frequency of its meetings. 
Adverse events  
An adverse event (AE) was defined as any untoward or unfavourable medical occurrence in a 
human subject, including signs and symptoms which are temporally associated with the research 
procedure or trial intervention, whether or not considered related to the subject’s participation in the 
research.  Participants were monitored for AEs on each scheduled follow up day. All symptoms or 
signs reported or observed were assessed by the study Field Assistant and recorded. If help is 
needed, was sought from the study nurse. 
Serious adverse events (SAEs) 
A SAE was defined as any AE that was life-threatening or results in death or requires hospitalisation 
or prolongation of hospitalisation, was a persistent or significant disability/ incapacity or a congenital 
anomaly/birth defect. Reported maternal deaths, miscarriages, stillbirths were recorded as SAEs. All 
SAEs were investigated by the trial physician. 
Assessment of intensity 
The trial nurses with the support of the PI and other member of the Keneba clinical team, assessed 
the severity or intensity of the AEs and laboratory changes as follows and document them into the 
AE form: 
 
Grade Description 
1 Mild Awareness of sign or symptom, but easily tolerated 
2 Moderate Enough discomfort to cause interference with usual activity 
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3 Severe Incapacitating with inability to work or do usual activity 
4 Life-threatening This grade was considered as SAE  
 
The term “severe” was often used to describe the intensity (severity) of a specific event (as in mild, 
moderate, or severe myocardial infarction); the event itself, however, may be of relatively minor 
medical significance (such as severe headache). This is not the same as “serious”, which was 
based on the outcome or criteria defined under the SAE definition. An event was considered serious 
without being severe if it conforms to the seriousness criteria; similarly, severe events that did not 
conform to the criteria were not necessarily serious. Seriousness (not severity) serves as a guide for 
defining regulatory reporting obligations. 
Assessment of causality 
Every effort was made by the PI and team to explain each AE and assess its causal relationship to 
administration of the trial intervention. This explanation was based on the type of event, the 
relationship of the event to the time of trial intervention, and the natural history of the underlying 
diseases, concomitant therapy, etc.  The results were documented on the CRF.  The relationship of 
an AE to the investigational product was assessed according to the following definitions:  
Not related 
• No temporal relationship to trial intervention; and  
• Event could be explained by alternate aetiology (clinical state, environmental 
or other interventions).  
Unlikely related 
• Temporal relationship to trial intervention improbable (but not impossible); 
but 
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• Disease or other products provide plausible explanations; 
Possibly Related 
• Reasonable temporal relationship to trial intervention; but  
• Event could also be explained by alternate aetiology (clinical state, 
environmental or other interventions);  
Probably Related 
• Reasonable temporal relationship to trial intervention; and  
• Event could not be explained by alternate aetiology (clinical state, 
environment, or other interventions);  
Definitely Related 
• Reasonable temporal relationship to trial intervention; and 
• Event could not be explained by alternate aetiology (clinical state, 
environmental or other interventions); or  
• Event could be confirmed with a positive re-challenge test, where applicable. 
The participants were instructed to contact the field assistant or a member of the study team, should 
the participant manifest any signs or symptoms they perceive as severe during the period extending 
from performance of the first trial procedure to the end of the study. 
 
All findings observed or reported from the day of the first administration of the trial intervention were 
recorded on the CRF by the team. Whenever possible, AEs were documented in terms of a 
diagnosis or syndrome rather than multiple symptoms that are clear manifestations of the same 
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diagnosis/syndrome. In case signs and symptoms are reported by the participants, a medical 
diagnosis was obtained by the nurses and PI. If a diagnosis cannot be obtained then each sign or 
symptom was recorded as separate events. 
 
The action taken (e.g. discontinuation of investigational product, withdrawal of the participant from 
the trial, requirement of concomitant medication or treatment, others) was recorded on the 
appropriate section of the CRF. If hospitalisation or its prolongation was required this was reported 
as a SAE.  
 
All AEs were followed until resolution of the event and/or the end of the trial. The outcome was 
assessed as follows: 
• Resolved 
• Resolved with sequelae 
• Ongoing 
• Death 
• Lost to follow up 
 
Treatment for any AE and SAE was recorded on the appropriate section of the CRF. 
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Reporting procedures 
The PI reported all SAEs without filtration, whether or not related to the trial intervention, within 24 
hours of becoming aware of the event to the DSMB and the Sponsor. Plan was that if the SAE was 
related to the trial intervention, the Ethics Committee be notified according to their procedures.  
 
The minimum information required for this initial SAE report was: 
• Trial number and (short) title 
• Participant’s ID 
• Date and time of onset 
• Description of the event (clinical history, associated signs and symptoms) 
• Intervention product administered 
 
The PI was not to wait for additional information to fully document the event before notifying. The 
report was then followed by submission of a completed SAE Report Form as soon as possible, 
detailing relevant aspects of the SAE in question. We reported all actions taken by the PI and the 
outcome of the event.  
For documentation of the SAE, any actions taken, outcome and follow-up, the SAE Report Forms 
was used. All follow-up activities were reported, where necessary on one or more consecutive SAE 
report forms in a timely manner. All fields with additional or changed information were completed 
and the report form forwarded to the DSMB within 5 calendar days after receipt of the new 
information. We obtained hospital case records and autopsy reports including verbal autopsy, where 
applicable. 
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Withdrawal of participants   
A study participant was discontinued from participation in the study if: 
• Any clinical significant adverse event (AE), laboratory abnormality, intercurrent 
• illness, or other medical condition or situation occurs such that continued 
• participation in the study would not be in the best interest of the participant 
• Development of any exclusion criteria 
Discontinuation criteria 
Participant’s premature termination 
A participant had the right to stop participating in the study at any time without giving a reason and 
this did not affect the medical care that would normally be received. The trial team or the DSMB 
withdrew participants from the study when deemed necessary at any time taking in to consideration 
the reasons mentioned below. We documented all the reasons for a participant’s premature 
termination on the appropriate page of the CRF and specified which of the following possible 
reasons were responsible for the premature termination:  
• Serious Adverse Event  
• Adverse Event  
• Participant’s consent withdrawal  
• Development of withdrawal criterion 
• Migrated/moved from the study area  
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• Lost to follow-up  
A 'lost to follow-up' was any participant who completed all protocol specific procedures up to the 
administration of the investigational product or intervention, but was then lost during the study 
period to any further follow-up, with no safety information and no efficacy endpoint data ever 
available  
 
In case the participant decided to withdraw participation or consent during the study, we did not 
work on that participant’s samples without permission, but any information that was already 
generated from the samples was kept and used. The study physician was responsible for asking for 
tests for the participant’s safety. The PI had the responsibility to inquire about the reason for any 
withdrawal and follow-up with the participant regarding any unresolved AEs. 
 
We did not collect any specific data for withdrawn participants. We did not replace subjects as our 
sample size calculation took into account a dropout rate of 15%. 
Study discontinuation 
The rules for study termination or discontinuation were set by the DSMB in the DSMB Charter.   
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Appendix 6: Statistical Analysis Plan (SAP) 
   
A randomised controlled trial comparing two screen-and-treat iron supplementation based 
on plasma hepcidin concentration with a daily universal iron supplementation in pregnant 
Gambian women 
 
 
Brief title: Hepcidin and anaemia in pregnancy (HAPn) 
 
  
 
 
   
 
 
Statistical Analysis Plan(SAP) 
 
Version: 1.0 
Date: 4 July 2017 
 
Prepared by: Mr Amat Bah, PhD student and Principal Investigator 
 
Approved by: Prof. Andrew M. Prentice, Supervisor 
  Dr Hans Verhoef, Statistical adviser to student 
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Abbreviations 
AE Adverse Event 
APGAR Appearance, Pulse,  Grimace, Activity, Respiration 
AUCROC Area Under the Curve 
EDTA Ethelenediamine tetraacidic acid 
ENID Early Nutrition and Immune Development 
HAPn Hepcidin and anaemia in pregnancy 
IQR Inter Quartile Range 
ITT Intent To Treat 
LMP Last Menstrual Period 
MCV Mean Corpuscular Volume 
mITT Modified Intent To Treat 
PI Principal Investigator 
PP Per Protocol 
RDT  Rapid Diagnostic Test 
ROC Receiver Operating Characteristics  
SAE Serious Adverse Event 
SD Standard Diviation 
SOP Standard Operating Procedure 
TSAT Transferrin Saturation 
UNIMMAP UNU/UNICEF/WHO international multiple micronutrient preparation 
WHO World Health Organisation 
 
 
Overview 
Anaemia affects all population groups but those at greatest risk are pregnant women and children. 
For women, anaemia is associated with poor pregnancy and birth outcomes including premature 
delivery, low birth weight and increased perinatal mortality. The most significant contributor to the 
onset of anaemia is iron deficiency[1]. WHO recommends iron supplementation for all pregnant 
women (60mg/d iron and 400ug/d folic acid) living in areas where anaemia rates exceed 40%.  There 
are concerns that such universal iron supplementation can increase risks of haemoconcentration, 
gestational diabetes and pre-eclampsia to pregnant women[130, 134]. Therefore, there is a need to 
explore screen-and-treat options to minimise iron exposure during pregnancy using an overall lower 
dosage of iron that would achieve non-inferior benefits as the WHO recommendation. There is some 
evidence that smaller doses of 30mg iron daily could achieve similar results as the daily 60mg iron[49]. 
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Furthermore, WHO recommends supplementation with daily doses between 30–60mg iron for 
pregnant women[132]. Evidence also suggest that the use of multiple micronutrient supplements with 
three or more micronutrients is associated with a 39% risk reduction in maternal anaemia compared 
with placebo or with two micronutrients or fewer (relative risk 0·61, 95% CI 0·52—0·71). Multiple 
micronutrient supplementation is also known to result in a decrease in the risk of low-birth weight 
babies (0·83, 0·76—0·91) and small-for-gestational-age babies (0·92, 0·86—0·99)[148]. Therefore, 
this trial used the UNICEF/WHO/UNU international multiple micronutrient preparation (UNIMMAP) 
containing either 60mg or 30mg or 0mg iron per day. 
 
However, there is a lack of agreement on how to best assess iron deficiency in the presence of 
infection-induced inflammation. Hepcidin, a peptide hormone, is believed to have the potential of being 
an ideal index for ‘safe and ready to receive’ iron. In this trial, we used a predetermined cut-off value 
for hepcidin concentration of <2·5µg/L as a threshold to decide on whether or not to receive iron. This 
cut-off value is based on the analysis of sera from 395 pregnant women participating in the ENID 
study[165] with samples available for 3 time points (14 weeks, 20 weeks and 30 weeks gestation).  A 
receiver operating characteristics (ROC)-curve was generated to measure the area under the curve 
(AUCROC).  Method described elsewhere[117]. 
 
This study aims to evaluate the hypothesis that a screen-and-treat approach to iron supplementation 
below the pre-determined hepcidin cut-off value (<2·5µg/L), is non-inferior to the reference arm (WHO-
recommended universal iron supplementation) in preventing anaemia and iron deficiency at a lower 
dose and hence improve safety and tolerability after 12 weeks intervention with haemoglobin 
concentration as the primary endpoint.   
 
Objectives: 
Primary objectives: 
1. To evaluate if a screen-and-treat supplementation strategy (i.e., weekly screening of plasma 
hepcidin concentration for 12 weeks, each time succeeded by daily supplementation for 7 days 
using micronutrients with or without  60mg iron as ferrous fumarate, depending on plasma 
hepcidin concentration) is non-inferior to daily universal supplementation (i.e. micronutrients 
including 60mg iron as ferrous fumarate) regarding haemoglobin concentration at the end of 12 
weeks of intervention; 
 
2. To evaluate if a screen-and-treat supplementation strategy (as above, with 30mg iron instead of 
60mg iron) is non-inferior to daily universal supplementation (i.e. micronutrients including 60mg 
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iron as ferrous fumarate) regarding haemoglobin concentration at the end of 12 weeks of 
intervention; 
 
Secondary objectives: 
3. To compare screen-and-treat supplementation strategies with daily supplementation with 
regards to anaemia; 
4. To compare screen-and-treat supplementation strategies with daily supplementation with 
regards to iron status; 
5. To compare screen-and-treat supplementation strategies with daily supplementation 
regarding the number of events per week of self-reported side-effects, adverse or serious 
adverse events; 
6. To compare screen-and-treat supplementation strategies with daily supplementation 
regarding adherence or compliance; 
7. To compare exposure to supplemental iron in the two screen-and–treat groups. 
 
Population and sample 
Participants for the study are women of Jarra West and Kiang East (rural Gambia), identified by nurse 
midwives as they visited the Reproductive and Child Health clinics to register and book their 
pregnancies. They were pregnant women in the age range 18–45 years with gestational age of 14–
22 weeks as assessed by the reported first date of last menstrual period (LMP) and by fundal height 
assessment.   
 
Pregnant women were ineligible for randomisation and excluded if: unlikely to be resident in the study 
area for the entire duration of the intervention period; severely anaemic (haemoglobin concentration 
<70g/L); seriously ill (infectious disease of clinical significance) or suffering from a chronic disease; or 
have pregnancy complications (e.g. pre-eclampsia); or if already participating in another study. 
 
 
Randomisation 
Recruited women were randomly allocated, using computer-generated numbers to one of 3 
intervention arms ‘X’, ‘Y’ and ‘Z’ (representing the treatment arm ‘A’, ‘B’ and ‘C’ below), based on a 
stratified permuted block design with a 1:1:1 allocation ratio, balanced by the haemoglobin 
concentration and gestational age at baseline. To achieve this, at each day of recruitment, subjects 
were categorised into four strata formed by cross-classification by haemoglobin class (above and 
below the median haemoglobin of the respective day) and gestational age (14–18 weeks, 19–22 
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weeks). In each of the 4 classes, the women were randomly assigned to the 3 treatment arms using 
a predetermined block randomisation.To minimise biases the study was double blinded  
 
Interventions 
The groups/treatment arms received the following interventions: 
A) Daily supplementation with UNU/UNICEF/WHO international multiple micronutrient 
preparation (UNIMMAP) capsules containing 60mg iron as ferrous fumarate (reference 
treatment) for 12 weeks; 
 
B) Weekly screening of plasma hepcidin concentration for 12 weeks, each time succeeded by 
daily supplementation for 7 days with UNIMMAP containing (60mg iron as ferrous fumarate) 
or placebo (no iron), depending on plasma hepcidin concentration being <2·5µg/L or ≥2·5µg/L, 
respectively; 
 
C) Screen-and-treat supplementation as in group b), but with UNIMMAP containing an iron dose 
of 30mg/day instead of 60mg/day.  
 
 
Field procedures 
Collection of data and samples started 16th June 2014 and ended 3rd March 2016, and this is 
schematically shown in Figure 1. We identified and screened pregnant women at first antenatal 
care visits at two health facilities. During screening: we obtained prior informed consent; collected 
demographic information; and provided a long-lasting insecticide-treated mosquito net to each 
participant. We conducted a medical examination (including assessment of gestational age by last 
menstrual period (LMP) and fundal height measurement), and collected a 5-7mL venous blood 
sample in EDTA tubes. For women who were excluded, we recorded reasons for not randomised 
when possible. 
 
We used the blood samples to determine haemoglobin concentrations in the field by photometer 
(HemoCue) and to assay the presence of P. falciparum antigens by rapid diagnostic tests (RDTs; 
SD Bioline Malaria Ag P.f.).  If the result of the rapid diagnostic test was positive, we prepared a 
blood slide for microscopic examination.  At the laboratory in Keneba, we produced a haemogram 
(haemoglobin concentration, blood cell counts, mean corpuscular volume, etc.) using an automated 
blood analyser (Medonic M Series). We measured serum hepcidin concentration by ELISA 
(Hepcidin-25 (human) EIA Kit, Bachem) using a Thermofisher Scientific Multiskan FC Microplate 
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Photometer with a detection range 0·049 - 25·0ug/L). We assessed in vitro growth of P. falciparum 
in washed red blood cells. We stored plasma at –20°C for subsequent determination of plasma 
markers (concentrations of soluble transferrin receptor, iron, etc). 
 
The intervention started at Day 0 (day of recruitment and randomisation) and continued for 84 days 
or until delivery, whichever came first. At Day 2 and thereafter weekly, each participating woman 
was seen weekly by fieldworkers, who gave a 1-week supply of supplements, counted supplements 
remaining from the previous week, measured axillary temperature, and recorded self-reported side 
effects that occurred in the preceding week on a standardised form (Figure 1). At Days 14, 49 and 
84, we collected additional venous blood for assessments and storage of plasma samples as 
described for baseline. At Day 7 and thereafter weekly (except for the dates when venous blood was 
collected), field staff collected peripheral blood samples by finger prick. At each time point, we 
assessed P falciparum infection by rapid dipstick test, and we measured hepcidin concentrations in 
plasma samples within 2 days of blood collection. Depending on hepcidin concentrations being 
<2·5μg/L or ≥2·5μg/L, the woman received a subsequent 1-week supplementation cycle with or 
without iron, respectively. 
 
At delivery, we recorded the place of delivery, delivery mode, complications, birth weight and 
APGAR  (appearance, pulse,  grimace, activity, respiration) score. 
 
For adverse events/serious adverse events, we recorded a description, duration and relation to 
intervention.  Where possible, we recorded reasons for being lost to follow up. 
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FIGURE 
1.  Collection of samples and data within the HAPn study 
 
 
Data cleaning 
The PI and study team will inspect the data using descriptive statistics and histograms to detect 
missing values, incorrectly entered values and impossible outliers. Data will be corrected if needed 
and if possible using source data available from the field and laboratory. 
 
Blind review 
In a preliminary, blind review of the data, we will calculate descriptive statistics at baseline and at the 
end of intervention by group (A, B, C).  This review will help in the finalisation of the statistical plan, 
and in the identification of imbalances in baseline factors that are prognostic for outcomes. 
 
Data locking 
Once the data is cleaned to the satisfaction of the PI, his supervisors and the trial statistician, the data 
will be locked per Medical Research Council procedure (SOP-DMA-019) to prevent any further 
interference with the data set. If there is need to unlock the database later, provision of the SOP must 
be used. 
 
 
 
Hand-out and count of supplements; assessment of axillary temperature and adverse effects
0 847 14 21 28 35 42 49 56 63 70 77 Days since randomisation
2 9 16 23 30 37 44 51 58 65 72 79
Hepcidin measurement; collection of peripheral blood sample *
Randomisation End of study
Anthropometry; collection of venous blood sample **
* To determine haemoglobin concentration (HemoCue) and P. falciparum antigenaemia by rapid dipstick test
** For haemogram and to determine concentrations of iron markers and inflammatory markers in plasma or serum
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Missing values and outliers 
All missing values and outliers present after the locking of the data shall be maintained.  One set of 
analysis will be performed with the missing values for per protocol analysis. In a copy of this dataset, 
missing values will be replaced by multiple imputations to allow intention-to-treat (ITT) analysis. Both 
analyses will be reported.  
 
ITT analysis generally leads to intervention effects being underestimated, which we consider 
undesirable to assess effects on adverse events. Thus, emphasis in the interpretation of effects on 
adverse events will be on the per protocol analysis. 
 
We will use a modified ITT (mITT) analysis, i.e. excluding participants who were lost to follow-up or 
withdrawn before the first dose of supplementation was received. We will use Multivariate Imputation 
by Chained Equations using Stata 14), with replacement of missing data under a missing-at-random 
assumption by multiple imputation. We will log-transform variables as necessary to normalize 
distributions.  To ensure convergence to a stationary distribution, we will use a burnin of 1000. We 
shall also test different number of imputations that ensures the Monte Carlo error estimates follow the 
practical guidelines from White et al. [182]. A list of variables used in the imputation model will be 
submitted as Supplementary material. For binary outcomes, multiple imputations will yield an integer 
number of cases per iteration, but pooled estimates from multiple iterations may result in these 
numbers to be estimated in non-integer values. Because this precludes computation of confidence 
intervals for differences in proportions, we will instead calculate differences in means under the 
assumption that binary outcome variables have a Bernoulli distribution.  
 
Definitions  
1. Anaemia: haemoglobin concentration <110g/L. 
2. Iron status: plasma ferritin concentration at Day 84, adjusted for the degree of inflammation 
and among non-inflamed.  
3. Iron deficiency anaemia (IDA): iron deficiency in the presence of anaemia 
4. Iron receptivity: ability or readiness to absorb and utilise iron by the body, as indicated by 
plasma hepcidin concentration; 
5. Tissue iron deficiency: iron deficiency due to impaired physiological systems for transporting 
iron to target tissues, as indicated by plasma soluble transferrin receptor concentration, with 
adjustment for the degree of inflammation.  
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Participant flow 
We will produce a flowchart describing the progress through various phases of the trial (i.e. enrolment, 
intervention allocation, follow-up, and data analysis) of the three intervention groups as per the 
CONSORT guidelines (Figure 2). 
 
We will report:  
• Number of participants identified or screened 
• Number of participants consented   
• Number of participants enrolled  
• Number of participants randomised to the 3 study arms 
• Number lost to follow-up and reasons 
• Number of births that occurred before the end of the 84-day intervention period for each of 
the study arms 
• Summary of Adverse Events (AEs) 
• Summary of Serious Adverse Events (SAEs) 
• Number that completed study 
• Number analysed 
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Figure 2: Flowchart  
 
 
Description of baseline characteristics 
We will report in a table describing the following baseline characteristics by intervention group: 
maternal age (continuous variable), gestational age (continuous variable), parity, gravida (both 
continuous and categorical), weight, height (continuous), haemogram markers (haemoglobin, mean 
corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, 
red blood cells, red blood cell distribution width,  haematocrit, white blood cells); (both continuous and 
categorical), genotype (categorical), iron and inflammation markers (both continuous and categorical) 
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ethnicity categorical), Plasmodium infection (binary), and provision of impregnated mosquito nets 
(binary). 
 
For all groups, we will report sample size. For ferritin concentrations, we will also report values 
adjusted for C-reactive protein and α1-acid glycoprotein. Ferritin when there is inflammation CRP 
>5mg/L and AGP ≥1g/L. For normally distributed variables, we will report group means (SD). For 
variables with a lognormal distribution, we will report geometric means (geometric SD). For continued 
variables that are not normally distributed, or that cannot be normalised by log-transformation, we will 
report medians with corresponding 25th- and 75th-centiles that indicate the limits of the IQR.  
 
 
Description of outcomes 
We will report the following outcomes by intervention group, (with descriptive parameters as described 
above): 
1. Haemogram markers (haemoglobin concentration, erythrocyte count, MCV); 
2. Iron markers (plasma concentrations of ferritin, iron, soluble transferrin receptors, total iron 
binding capacity, unsaturated iron binding capacity, transferrin); 
3. Inflammation markers (C-reactive protein, α1-acid glycoprotein; leukocyte count) 
4. Serum hepcidin concentration; 
5. Anthropometry 
6. Birth weight. 
 
 
For continuous outcome variables measured at the end of the intervention, we will compare pairs of 
intervention groups by estimating the difference in means assuming a t-distribution of the outcome. A 
logarithmic transformation will be applied to log-normally distributed variables.  
 
The analysis for the primary end point (haemoglobin at Day 84) will be based on a test for non-
inferiority with a per-protocol analysis.  As per acceptable practice, a modified intent-to-treat analysis 
will also be performed on the randomised population. 
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Primary analysis: 
The primary non-inferiority endpoint is pregnancy-adjusted haemoglobin concentration at Day 84.  
Groups will be compared using linear regression analysis, with intervention entered as a dummy-
coded categorical variable and using the control arm (universal daily supplementation) as the 
reference group. To indicate non-inferiority, the lower limit of the 95·0% confidence interval for the 
difference in mean haemoglobin concentration between either of the screen-and-treat arms and the 
reference arm shall be above -5·0 g/L. 
 
 
Secondary analyses 
Groups will be compared using linear regression analysis as described below for secondary outcomes 
measured at Day 84 (plasma concentrations of ferritin, soluble transferrin receptor and total transferrin 
saturation (TSAT), with adjustments for inflammation (where appropriate) as described below. 
 
Thus, we will use linear regression analysis indicated by concentrations of C-reactive protein and α1-
acid glycoprotein, with arbitrarily selected reference values of 5µg/L and 1mg/L, respectively. Results 
will be reported for adjusted ferritin concentration as a continuous variable and dichotomised as iron 
deficient or iron replete (<15µg/L and ≥15µg/L, respectively; WHO 2011)[183]. In addition, we will 
conduct a stratified analysis by using unadjusted ferritin concentration <15µg/L but restricting analysis 
to those without inflammation.  
 
We will use mixed-effect linear regression models to compare intervention groups regarding the 
development over time of continuous outcomes (haemoglobin concentration, plasma concentrations 
of ferritin, soluble transferrin receptor, transferrin, total iron saturation), with adjustment for baseline 
values. The models will include main terms for time and intervention group, and their product term to 
assess changes in the intervention effect over time. In these analyses, outcome variables will be log-
transformed as appropriate.  
 
The hepcidin values may possibly be censored due to the range of the competitive ELISA (Bachem 
Hepcidin-25; now marketed by Peninsula Laboratories International) which was used in quantifying 
the plasma levels. Hence, in such an eventuality, we would use a Tobit model to investigate any 
differences in plasma hepcidin levels between groups, otherwise it would be assessed as other 
continuous variables. 
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Safety analysis 
We will perform analysis using rate and rate ratios for the side effects (morbidity assessment), AEs 
and SAEs. Simple comparison of rates of side effects, AEs and SAEs would be used to assess 
differences between groups. We shall use Poisson regression to determine the number of events per 
person weeks. In the event of over-dispersion, we shall use a negative binomial model instead. We 
will only perform crude comparisons as we believe the randomisation would adequately address most 
confounding. However, we expect that the observation period of the women in the study would vary 
and would thus be a possible confounder for this analysis. We shall address any imbalance in the 
observation periods of the women by using an exposure variable for the regression models. 
Comparisons between groups Y and Z vs. group X would be reported as rate ratios. 
We will analyse P falciparum growth in serum (difference between in vitro growth rates at Days 0, 14, 
49 and 84) to determine relationship to study arms and also Ex vivo growth of sentinel bacteria 
(difference between in vitro growth rates at Days 0, 14, 49 and 84) 
 
 
Adherence assessment 
We will conceive adherence as the extent to which the participant’s history of supplementation 
coincided with the prescribed supplementation. We will estimate adherence as the number of days 
that supplements were consumed (as indicated by tablet count) divided by the number of days of 
follow-up (minus 2 days to account for the first two days after randomisation, when supplementation 
was put on hold depending on the results of the first hepcidin concentration assessment). In this 
assessment, women who completed the intervention as scheduled; left the study prematurely due to 
refusals; left due to medical or unknown reasons; or who were withdrawn because of poor compliance, 
contributed follow-up time until the scheduled end of intervention (i.e., 85 days, including Day 0). For 
women who left the study prematurely for reasons that we considered unrelated or unlikely to be 
related to supplementation use (i.e., delivery or emigration), we will calculate follow-up time as the 
time until leaving the study. Summary measures (e.g., mean, percentiles) of adherence calculated for 
individual women are biased because of differences between women in follow-up time. Thus, we will 
estimate group adherence as the average number of days that supplements were consumed divided 
by the average days of follow-up time. Thus defined, group adherence is essentially an average of 
individuals’ adherence weighted by observation time. 
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Exposure to supplemental iron 
For each of the groups that received screen-and-treat supplementation, we calculated the reduction 
in prescribed iron supplements due to screen-and-treat approach as the percentage of supplements 
prescribed that contained no iron.   
 
 
Further exploratory analysis 
• Primary endpoints adjusted for C-reactive protein, Alpha 1-acid glycoprotein and malaria (we 
decided apriori that the primary endpoints will not be adjusted for the above.  However, we 
wish as part of an exploratory analysis to adjust for them) 
• Ferritin  
• Soluble transferrin receptor 
• Transferrin saturation (TSAT)  
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Appendix 7:  Pictures from the HAPn trial (permission for reproducing the photographs was 
ganted) 
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